
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Phase 1/2 study of H3B-6545 in women with locally advanced/metastatic estrogen receptor-positive, HER2-negative breast cancer - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="D2E4B5D58AF3AAF305B5D50038327BCA.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="brcnres">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12363031/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Breast Cancer Research : BCR">
<meta name="citation_title" content="Phase 1/2 study of H3B-6545 in women with locally advanced/metastatic estrogen receptor-positive, HER2-negative breast cancer">
<meta name="citation_author" content="Erika Hamilton">
<meta name="citation_author_institution" content="Breast Cancer Research Program, Sarah Cannon Research Institute, Nashville, TN USA">
<meta name="citation_author_institution" content="Sarah Cannon Research Institute, 335 24th Avenue North, Suite 300, Nashville, TN 37203 USA">
<meta name="citation_author" content="Timothy Pluard">
<meta name="citation_author_institution" content="Koontz Center for Advanced Breast Cancer, Saint Luke’s Cancer Institute, Kansas City, MO USA">
<meta name="citation_author" content="Judy S Wang">
<meta name="citation_author_institution" content="Hematology and Oncology, Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL USA">
<meta name="citation_author" content="Aki Morikawa">
<meta name="citation_author_institution" content="Department of Internal Medicine, University of Michigan, Ann Arbor, MI USA">
<meta name="citation_author" content="Stephen Johnston">
<meta name="citation_author_institution" content="Breast Unit, Royal Marsden NHS Foundation Trust, London, UK">
<meta name="citation_author" content="E Claire Dees">
<meta name="citation_author_institution" content="Department of Medicine, Division of Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC USA">
<meta name="citation_author" content="Christos Vaklavas">
<meta name="citation_author_institution" content="Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT USA">
<meta name="citation_author" content="Anne Armstrong">
<meta name="citation_author_institution" content="Division of Cancer Studies, University of Manchester, Manchester, UK">
<meta name="citation_author_institution" content="Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK">
<meta name="citation_author" content="Pamela Munster">
<meta name="citation_author_institution" content="Division of Hematology and Oncology, University of California, San Francisco, CA USA">
<meta name="citation_author" content="Nisha Unni">
<meta name="citation_author_institution" content="Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX USA">
<meta name="citation_author" content="Gail S Wright">
<meta name="citation_author_institution" content="Medical Oncology, Florida Cancer Specialists &amp; Research Institute/Sarah Cannon Research Institute, Trinity, FL USA">
<meta name="citation_author" content="Fadi Kayali">
<meta name="citation_author_institution" content="Hematology and Oncology, Florida Cancer Specialists, Lakewood Ranch/Sarasota, FL USA">
<meta name="citation_author" content="Tingting Song">
<meta name="citation_author_institution" content="Eisai Inc, Nutley, NJ USA">
<meta name="citation_author" content="Yuanxin Rong">
<meta name="citation_author_institution" content="Eisai Inc, Nutley, NJ USA">
<meta name="citation_author" content="Kohei Yamaguchi">
<meta name="citation_author_institution" content="Eisai Co., Ltd, Tokyo, Japan">
<meta name="citation_author" content="Dejan Juric">
<meta name="citation_author_institution" content="Massachusetts General Hospital, Harvard Medical School, Boston, MA USA">
<meta name="citation_publication_date" content="2025 Aug 19">
<meta name="citation_volume" content="27">
<meta name="citation_firstpage" content="151">
<meta name="citation_doi" content="10.1186/s13058-025-02069-8">
<meta name="citation_pmid" content="40830892">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12363031/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12363031/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12363031/pdf/13058_2025_Article_2069.pdf">
<meta name="description" content="Although endocrine therapies, alone or in combination with CDK4/6 inhibitors, have led to notable improvements in the treatment of estrogen receptor-positive (ER+) breast cancer, progression is inevitable for most patients. We report dose escalation ...">
<meta name="og:title" content="Phase 1/2 study of H3B-6545 in women with locally advanced/metastatic estrogen receptor-positive, HER2-negative breast cancer">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Although endocrine therapies, alone or in combination with CDK4/6 inhibitors, have led to notable improvements in the treatment of estrogen receptor-positive (ER+) breast cancer, progression is inevitable for most patients. We report dose escalation ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12363031/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12363031">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1186/s13058-025-02069-8"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/13058_2025_Article_2069.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12363031%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12363031/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12363031/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12363031/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-brcnres.png" alt="Breast Cancer Research : BCR logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Breast Cancer Research : BCR" title="Link to Breast Cancer Research : BCR" shape="default" href="https://doi.org/10.1186/s13058-025-02069-8" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Breast Cancer Res</button></div>. 2025 Aug 19;27:151. doi: <a href="https://doi.org/10.1186/s13058-025-02069-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1186/s13058-025-02069-8</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22Breast%20Cancer%20Res%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Breast%20Cancer%20Res%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Breast%20Cancer%20Res%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Breast%20Cancer%20Res%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Phase 1/2 study of H3B-6545 in women with locally advanced/metastatic estrogen receptor-positive, HER2-negative breast cancer</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Hamilton%20E%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Erika Hamilton</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Erika Hamilton</span></h3>
<div class="p">
<sup>1</sup>Breast Cancer Research Program, Sarah Cannon Research Institute, Nashville, TN USA </div>
<div class="p">
<sup>17</sup>Sarah Cannon Research Institute, 335 24th Avenue North, Suite 300, Nashville, TN 37203 USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Hamilton%20E%22%5BAuthor%5D" class="usa-link"><span class="name western">Erika Hamilton</span></a>
</div>
</div>
<sup>1,</sup><sup>17,</sup><sup>✉</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Pluard%20T%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Timothy Pluard</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Timothy Pluard</span></h3>
<div class="p">
<sup>2</sup>Koontz Center for Advanced Breast Cancer, Saint Luke’s Cancer Institute, Kansas City, MO USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Pluard%20T%22%5BAuthor%5D" class="usa-link"><span class="name western">Timothy Pluard</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wang%20JS%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Judy S Wang</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Judy S Wang</span></h3>
<div class="p">
<sup>3</sup>Hematology and Oncology, Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wang%20JS%22%5BAuthor%5D" class="usa-link"><span class="name western">Judy S Wang</span></a>
</div>
</div>
<sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Morikawa%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Aki Morikawa</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Aki Morikawa</span></h3>
<div class="p">
<sup>4</sup>Department of Internal Medicine, University of Michigan, Ann Arbor, MI USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Morikawa%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Aki Morikawa</span></a>
</div>
</div>
<sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Johnston%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Stephen Johnston</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Stephen Johnston</span></h3>
<div class="p">
<sup>5</sup>Breast Unit, Royal Marsden NHS Foundation Trust, London, UK </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Johnston%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Stephen Johnston</span></a>
</div>
</div>
<sup>5</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Dees%20EC%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">E Claire Dees</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">E Claire Dees</span></h3>
<div class="p">
<sup>6</sup>Department of Medicine, Division of Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Dees%20EC%22%5BAuthor%5D" class="usa-link"><span class="name western">E Claire Dees</span></a>
</div>
</div>
<sup>6</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Vaklavas%20C%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">Christos Vaklavas</span></a><div hidden="hidden" id="id7">
<h3><span class="name western">Christos Vaklavas</span></h3>
<div class="p">
<sup>7</sup>Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Vaklavas%20C%22%5BAuthor%5D" class="usa-link"><span class="name western">Christos Vaklavas</span></a>
</div>
</div>
<sup>7</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Armstrong%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id8"><span class="name western">Anne Armstrong</span></a><div hidden="hidden" id="id8">
<h3><span class="name western">Anne Armstrong</span></h3>
<div class="p">
<sup>8</sup>Division of Cancer Studies, University of Manchester, Manchester, UK </div>
<div class="p">
<sup>9</sup>Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Armstrong%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Anne Armstrong</span></a>
</div>
</div>
<sup>8,</sup><sup>9</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Munster%20P%22%5BAuthor%5D" class="usa-link" aria-describedby="id9"><span class="name western">Pamela Munster</span></a><div hidden="hidden" id="id9">
<h3><span class="name western">Pamela Munster</span></h3>
<div class="p">
<sup>10</sup>Division of Hematology and Oncology, University of California, San Francisco, CA USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Munster%20P%22%5BAuthor%5D" class="usa-link"><span class="name western">Pamela Munster</span></a>
</div>
</div>
<sup>10</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Unni%20N%22%5BAuthor%5D" class="usa-link" aria-describedby="id10"><span class="name western">Nisha Unni</span></a><div hidden="hidden" id="id10">
<h3><span class="name western">Nisha Unni</span></h3>
<div class="p">
<sup>11</sup>Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Unni%20N%22%5BAuthor%5D" class="usa-link"><span class="name western">Nisha Unni</span></a>
</div>
</div>
<sup>11</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wright%20GS%22%5BAuthor%5D" class="usa-link" aria-describedby="id11"><span class="name western">Gail S Wright</span></a><div hidden="hidden" id="id11">
<h3><span class="name western">Gail S Wright</span></h3>
<div class="p">
<sup>12</sup>Medical Oncology, Florida Cancer Specialists &amp; Research Institute/Sarah Cannon Research Institute, Trinity, FL USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wright%20GS%22%5BAuthor%5D" class="usa-link"><span class="name western">Gail S Wright</span></a>
</div>
</div>
<sup>12</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kayali%20F%22%5BAuthor%5D" class="usa-link" aria-describedby="id12"><span class="name western">Fadi Kayali</span></a><div hidden="hidden" id="id12">
<h3><span class="name western">Fadi Kayali</span></h3>
<div class="p">
<sup>13</sup>Hematology and Oncology, Florida Cancer Specialists, Lakewood Ranch/Sarasota, FL USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kayali%20F%22%5BAuthor%5D" class="usa-link"><span class="name western">Fadi Kayali</span></a>
</div>
</div>
<sup>13</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Song%20T%22%5BAuthor%5D" class="usa-link" aria-describedby="id13"><span class="name western">Tingting Song</span></a><div hidden="hidden" id="id13">
<h3><span class="name western">Tingting Song</span></h3>
<div class="p">
<sup>14</sup>Eisai Inc, Nutley, NJ USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Song%20T%22%5BAuthor%5D" class="usa-link"><span class="name western">Tingting Song</span></a>
</div>
</div>
<sup>14</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Rong%20Y%22%5BAuthor%5D" class="usa-link" aria-describedby="id14"><span class="name western">Yuanxin Rong</span></a><div hidden="hidden" id="id14">
<h3><span class="name western">Yuanxin Rong</span></h3>
<div class="p">
<sup>14</sup>Eisai Inc, Nutley, NJ USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Rong%20Y%22%5BAuthor%5D" class="usa-link"><span class="name western">Yuanxin Rong</span></a>
</div>
</div>
<sup>14</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Yamaguchi%20K%22%5BAuthor%5D" class="usa-link" aria-describedby="id15"><span class="name western">Kohei Yamaguchi</span></a><div hidden="hidden" id="id15">
<h3><span class="name western">Kohei Yamaguchi</span></h3>
<div class="p">
<sup>15</sup>Eisai Co., Ltd, Tokyo, Japan </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Yamaguchi%20K%22%5BAuthor%5D" class="usa-link"><span class="name western">Kohei Yamaguchi</span></a>
</div>
</div>
<sup>15</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Juric%20D%22%5BAuthor%5D" class="usa-link" aria-describedby="id16"><span class="name western">Dejan Juric</span></a><div hidden="hidden" id="id16">
<h3><span class="name western">Dejan Juric</span></h3>
<div class="p">
<sup>16</sup>Massachusetts General Hospital, Harvard Medical School, Boston, MA USA </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Juric%20D%22%5BAuthor%5D" class="usa-link"><span class="name western">Dejan Juric</span></a>
</div>
</div>
<sup>16</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="Aff1">
<sup>1</sup>Breast Cancer Research Program, Sarah Cannon Research Institute, Nashville, TN USA </div>
<div id="Aff2">
<sup>2</sup>Koontz Center for Advanced Breast Cancer, Saint Luke’s Cancer Institute, Kansas City, MO USA </div>
<div id="Aff3">
<sup>3</sup>Hematology and Oncology, Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL USA </div>
<div id="Aff4">
<sup>4</sup>Department of Internal Medicine, University of Michigan, Ann Arbor, MI USA </div>
<div id="Aff5">
<sup>5</sup>Breast Unit, Royal Marsden NHS Foundation Trust, London, UK </div>
<div id="Aff6">
<sup>6</sup>Department of Medicine, Division of Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC USA </div>
<div id="Aff7">
<sup>7</sup>Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT USA </div>
<div id="Aff8">
<sup>8</sup>Division of Cancer Studies, University of Manchester, Manchester, UK </div>
<div id="Aff9">
<sup>9</sup>Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK </div>
<div id="Aff10">
<sup>10</sup>Division of Hematology and Oncology, University of California, San Francisco, CA USA </div>
<div id="Aff11">
<sup>11</sup>Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX USA </div>
<div id="Aff12">
<sup>12</sup>Medical Oncology, Florida Cancer Specialists &amp; Research Institute/Sarah Cannon Research Institute, Trinity, FL USA </div>
<div id="Aff13">
<sup>13</sup>Hematology and Oncology, Florida Cancer Specialists, Lakewood Ranch/Sarasota, FL USA </div>
<div id="Aff14">
<sup>14</sup>Eisai Inc, Nutley, NJ USA </div>
<div id="Aff15">
<sup>15</sup>Eisai Co., Ltd, Tokyo, Japan </div>
<div id="Aff16">
<sup>16</sup>Massachusetts General Hospital, Harvard Medical School, Boston, MA USA </div>
<div id="Aff17">
<sup>17</sup>Sarah Cannon Research Institute, 335 24th Avenue North, Suite 300, Nashville, TN 37203 USA </div>
<div class="author-notes p"><div class="fn" id="_fncrsp93pmc__">
<sup>✉</sup><p class="display-inline">Corresponding author.</p>
</div></div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2025 Mar 4; Accepted 2025 Jun 9; Issue date 2025.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© Eisai Inc. 2025</div>
<p><strong>Open Access</strong> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <a href="https://creativecommons.org/licenses/by-nc-nd/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://creativecommons.org/licenses/by-nc-nd/4.0/</a>.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12363031  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40830892/" class="usa-link">40830892</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="Abs1"><h2>Abstract</h2>
<section id="sec1"><h3 class="pmc_sec_title">Background</h3>
<p id="Par1">Although endocrine therapies, alone or in combination with CDK4/6 inhibitors, have led to notable improvements in the treatment of estrogen receptor-positive (ER+) breast cancer, progression is inevitable for most patients. We report dose escalation and expansion data from a trial of H3B-6545 (a novel selective ER covalent antagonist that inactivates wild-type and mutant ERα) in women with locally advanced/metastatic ER+, HER2-negative breast cancer (BC).</p></section><section id="sec2"><h3 class="pmc_sec_title">Methods</h3>
<p id="Par2">This study was a multicenter, open-label, phase 1/2 trial. Women ≥ 18 years of age with ER+, HER2 − BC whose disease progressed on their most recent therapy were eligible. Prior therapy must have included at least 2 hormonal therapies (HTs), or 1 HT and 1 chemotherapy, or 1 HT and a CDK4/6 inhibitor. In phase 1, H3B-6545 was administered orally once daily at doses of 100–600 mg. In phase 2, the efficacy of the recommended phase 2 dose (RP2D) determined in phase 1 was examined in additional patients, including those with/without ERα mutation. The primary endpoints were RP2D determination (phase 1) and objective response rate (ORR) (phase 2, investigator-assessed per RECIST v1.1). Additional primary endpoints (phase 2) included progression-free survival (PFS) and overall survival (OS), per Kaplan-Meier estimates.</p></section><section id="sec3"><h3 class="pmc_sec_title">Results</h3>
<p id="Par3">151 Patients were treated across phases. During phase 1, 2 DLTs (drug eruption and fatigue, both grade 3) were observed at the 600 mg dose, and 450 mg was deemed the RP2D. In the total population (phases 1 and 2), all patients experienced ≥ 1 treatment-emergent adverse event (TEAE), and 50.3% had grade 3–4 TEAEs, with no grade 5 TEAEs observed. In phase 1, the overall ORR was 7.5% (95% CI 1.6–20.4). The ORR in all response-evaluable patients treated at 450 mg (<em>n</em> = 94) was 20.2% (95% CI 12.6–29.8). Patients with clonal <em>ESR1</em> Y537S mutation had an ORR of 32.1% (95% CI 15.9–52.4). For all patients who received H3B-6545 450 mg, median PFS was 4.6 months (95% CI 3.5–6.7) and median OS was 21.5 months (95% CI 16.6–25.5).</p></section><section id="sec4"><h3 class="pmc_sec_title">Conclusions</h3>
<p id="Par4">Results suggest that H3B-6545 may be further investigated as an endocrine therapy option for patients with previously treated metastatic ER + BC.</p></section><section id="sec5"><h3 class="pmc_sec_title">Trial registration</h3>
<p id="Par5"><a href="https://clinicaltrials.gov/ct2/show/NCT03250676" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT03250676</a>. Registered August 11, 2017.</p></section><section id="sec6"><h3 class="pmc_sec_title">Supplementary Information</h3>
<p>The online version contains supplementary material available at 10.1186/s13058-025-02069-8.</p></section><section id="kwd-group1" lang="en" class="kwd-group"><p><strong>Keywords:</strong> H3B-6545, Breast cancer, Endocrine therapy, HER2-negative, Estrogen receptor-positive</p></section></section><section id="Sec1"><h2 class="pmc_sec_title">Background</h2>
<p id="Par6">In total, approximately 70% of breast cancers (BCs) are driven by estrogen and express estrogen receptors (ERs) [<a href="#CR1" class="usa-link" aria-describedby="CR1">1</a>]. Several ER-directed therapies have been developed to antagonize the oncogenic ER alpha (ERα) function in pre- and postmenopausal women with locally advanced, recurrent, or metastatic cancer [<a href="#CR2" class="usa-link" aria-describedby="CR2">2</a>, <a href="#CR3" class="usa-link" aria-describedby="CR3">3</a>]. Although these endocrine therapies (ETs) have demonstrated efficacy and have become a cornerstone of ER-positive (+) BC treatment [<a href="#CR3" class="usa-link" aria-describedby="CR3">3</a>], innate and acquired resistance remains a major challenge [<a href="#CR4" class="usa-link" aria-describedby="CR4">4</a>]. Notably, <em>ESR1</em> gene mutations, which occur in approximately 20–40% of patients with metastatic BC who have received prior ET, have been linked to ET resistance [<a href="#CR5" class="usa-link" aria-describedby="CR5">5</a>]. In this population, the Y537S variant is particularly challenging to treat due to its propensity for constitutive activation of ER, its variable impact on the efficacy of selective ER degraders (SERD), and its observed association with poorer clinical outcomes [<a href="#CR3" class="usa-link" aria-describedby="CR3">3</a>, <a href="#CR6" class="usa-link" aria-describedby="CR6">6</a>–<a href="#CR8" class="usa-link" aria-describedby="CR8">8</a>]. Therefore, Y537S may be a more formidable resistance mechanism compared with other <em>ESR1</em> variants in the treatment of ER+, HER2- breast cancer.</p>
<p id="Par7">Although the addition of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors to ET (ET + CDK4/6 combination therapy) has led to notable improvements [<a href="#CR9" class="usa-link" aria-describedby="CR9">9</a>–<a href="#CR12" class="usa-link" aria-describedby="CR12">12</a>], progression remains inevitable for most patients [<a href="#CR13" class="usa-link" aria-describedby="CR13">13</a>]. Furthermore, patients with ER + advanced/metastatic BC treated with ET after prior CDK4/6 inhibitor treatment have shown limited or poor treatment efficacy outcomes [<a href="#CR3" class="usa-link" aria-describedby="CR3">3</a>, <a href="#CR7" class="usa-link" aria-describedby="CR7">7</a>]. Thus, novel agents are required to achieve additional improvements in treatment efficacy.</p>
<p id="Par8">H3B-6545, a novel selective ER covalent antagonist that inactivates wild-type and mutant ERα by targeting cysteine 530 and enforcing antagonist conformation, has shown promising activity as a monotherapy in the nonclinical setting [<a href="#CR14" class="usa-link" aria-describedby="CR14">14</a>]. Selective ER covalent antagonists (SERCAs) targeting cysteine 530 on the ER could be advantageous over non covalent SERDs for heavily pretreated ER+, HER2- breast cancer [<a href="#CR15" class="usa-link" aria-describedby="CR15">15</a>]. These covalent SERCAs could overcome resistance by ensuring irreversible binding, leading to stronger and longer-lasting antitumor effects. In heavily pretreated patients with likely endocrine resistance, SERCAs offer a novel mechanism with promising early clinical data, suggesting they could improve outcomes [<a href="#CR16" class="usa-link" aria-describedby="CR16">16</a>]. We report on an open-label, multicenter, phase 1/2 trial designed to identify the maximum tolerated dose (MTD)/the recommended phase 2 dose (RP2D) of H3B-6545 and to characterize the safety and efficacy of this monotherapy in heavily pretreated women with advanced or metastatic ER+, HER2 − BC. H3B-6545 previously showed a tolerable safety profile and preliminary antitumor activity in a subset of this patient population, including potentially increased activity in patients with <em>ESR1</em> Y537S clonal mutation [<a href="#CR16" class="usa-link" aria-describedby="CR16">16</a>], which has been associated with more aggressive disease relative to patients without the mutation [<a href="#CR6" class="usa-link" aria-describedby="CR6">6</a>]. We report full dose escalation and the expansion phase data from patients who received H3B-6545 monotherapy after disease progression on prior therapy, including patients with <em>ESR1</em> Y537S clonal mutation.</p></section><section id="Sec2"><h2 class="pmc_sec_title">Methods</h2>
<section id="Sec3"><h3 class="pmc_sec_title">Study design</h3>
<p id="Par9">The study design is summarized in Additional file 1 Fig. <a href="#MOESM1" class="usa-link">A1</a>. In phase 1 of this multicenter, phase 1/2 trial (<a href="https://clinicaltrials.gov/ct2/show/NCT03250676" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT03250676</a>; Registered August 11, 2017), dose escalation followed a standard 3 + 3 cohort design until both the MTD and the RP2D were determined. H3B-6545 was administered orally once daily (QD) at a dose of 100 mg to 600 mg. No food intake was allowed 2 h before and 2 h after the dose. Patients continued to receive the drug daily in 28-day cycles until disease progression, development of unacceptable toxicity, patient request, withdrawal of consent, or discontinuation of study by the sponsor. The MTD was defined as the highest dose at which no more than 1 of 6 patients experienced a dose-limiting toxicity (DLT) in the dose cohort. The RP2D was not to exceed the MTD and was agreed on by the Safety Review Committee based on an integrated evaluation of safety, tolerability, clinical benefit, pharmacokinetics, and pharmacodynamics data for all dose levels tested. In phase 2, the efficacy of the RP2D determined in phase 1 was examined in an expanded population of patients, including those with and without ERα mutation (including a clonal <em>ESR1</em> Y537S mutation). Patients who had received the selected RP2D in phase 1 were included in the analyses for phase 2. Additional patients with a clonal <em>ESR1</em> Y537S mutation were to be enrolled (per Protocol Amendment 6 [PA6]) to further characterize the efficacy of H3B-6545 in this subgroup of patients (Additional file 1 Fig. <a href="#MOESM1" class="usa-link">A1</a>).</p>
<p id="Par10">To assess the effect of food on pharmacokinetics (PK), 18 patients treated in phase 2 were assigned to the food-effect cohort. In the patients enrolled in the food-effect cohort, the patients were randomly assigned to receive the RP2D of H3B-6545 on cycle 1 day 15 (C1D15) in fasted or fed conditions, and each patient received the dose on cycle 1 day 22 (C1D22) in the untried conditions. For the “fasted” treatment, patients received a dose of H3B-6545 with 240 mL of water after an overnight fast of at least 10 h. For the “fed” treatment, patients were instructed to eat a high-fat meal (800–1000 calories, with approximately 50% of calories from fat) in 30 min or less and take a dose of H3B-6545 with 240 mL of water within 30 min after the start of the meal. In both treatments, no food was allowed for at least 4 h postdose. As a result of the PK interim analysis of the food-effect cohort, the effect of food on PK was limited. Therefore, patients enrolled under PA6 (and subsequent amendments) took their dose of H3B-6545 regardless of food conditions, whether fasting or after a meal.</p>
<p id="Par11">This study was approved by each research site’s institutional review board or independent ethics committee and performed in accordance with the principles of the World Medical Association Declaration of Helsinki. Informed consent was obtained from participants before study enrollment.</p></section><section id="Sec4"><h3 class="pmc_sec_title">Patients</h3>
<p id="Par12">Women ≥ 18 years of age with ER+, HER2 − BC whose disease progressed on their most recent anticancer therapy were eligible. ER + diagnosis was histologically and/or cytologically confirmed by a local laboratory, and HER2 − diagnosis was as defined by the American Society for Clinical Oncology College of American Pathologists guidelines [<a href="#CR17" class="usa-link" aria-describedby="CR17">17</a>]. Eligible patients had adequate bone marrow and organ function, an Eastern Cooperative Oncology Group performance status of 0 or 1, and were either postmenopausal or premenopausal/perimenopausal and concurrently given a luteinizing hormone-releasing hormone (LHRH) agonist starting at least 4 weeks before the start of trial therapy and planned to continue LHRH during the study. Prior therapy must have included a minimum of 2 hormonal therapies, or 1 hormonal therapy and 1 prior chemotherapy, or 1 hormonal therapy with a CDK4/6 inhibitor. Patients enrolled under PA6 or subsequent amendments received prior therapy, including at least 1 prior hormonal therapy and a CDK4/6 inhibitor. Up to 1 prior chemotherapy in the metastatic setting was allowed. Additional criteria for patients enrolled under PA6 or later amendments are included in Additional file Supplementary Methods.</p></section><section id="Sec5"><h3 class="pmc_sec_title">Study endpoints and assessments</h3>
<p id="Par13">The primary endpoints were the occurrence of DLTs as a function of the dose of H3B-6545 for determination of the MTD and/or RP2D (phase 1) and objective response rate (ORR, defined as the proportion of patients with a best overall response [BOR] of confirmed partial response [PR] or complete response [CR]; phase 2). Additional primary efficacy endpoints for phase 2 included duration of response (DOR), disease control rate (proportion of patients with a BOR of CR, PR, or stable disease ≥ 7 weeks), clinical benefit rate (CBR; the proportion of patients with a BOR of CR, PR, or durable stable disease [≥ 23 weeks]), progression-free survival (PFS, defined as the time from first dose date to the date of the first documentation of confirmed disease progression or death, whichever occurs first), and overall survival (OS, defined as the time from first dose date to the date of death [event] or date last known alive or data cutoff date, whichever comes first [censored]). Secondary endpoints included preliminary efficacy (phase 1), safety, and PK (phases 1 and 2).</p>
<p id="Par14">Tumor assessments were performed at baseline and every 8 weeks after starting the study drug until progression or unacceptable toxicity. Response and progression were assessed by the investigator using RECIST v1.1. Adverse events were monitored and recorded using the Common Terminology Criteria for Adverse Events version 4.03. Blood samples for PK assessment were collected at predose, 0.5, 1, 2, 4, 6, 8, 10, and 24 h postdose on cycle 1 day 1 (C1D1) and C1D15 in phase 1, or at the same time points on C1D15 and C1D22 for the patients enrolled in the food-effect cohort of phase 2. Plasma concentrations of H3B-6545 were measured by a validated liquid chromatography with tandem mass spectrometry method.</p></section><section id="Sec6"><h3 class="pmc_sec_title">Statistical analyses</h3>
<p id="Par15">Descriptive statistics for all continuous measures were tabulated and reported. Time-to-event endpoints (DOR, PFS, and OS) were reported using Kaplan-Meier estimates. For PFS, patients who did not have disease progression or death information were treated as right-censored observations at the time of the last response evaluation. Evaluation of safety was performed on the safety analysis set (all patients who received ≥ 1 dose of study drug) with the exception of the determination of the MTD during phase 1, which was based on all patients who were evaluable for DLTs in cycle 1 of phase 1. Statistical analyses were performed using SAS version 9.4 or later.</p>
<p id="Par16">PK parameters were calculated from plasma H3B-6545 concentrations by noncompartmental analysis using actual blood sampling times. The following PK parameters were calculated for each day: maximum observed plasma concentration (C<sub>max</sub>), time at which C<sub>max</sub> occurs (t<sub>max</sub>), and area under the plasma concentration-time curve from time zero to 24 h postdose (AUC<sub>(0–24 h)</sub>). Additionally, apparent total clearance following oral administration at steady state (CL/F) was calculated for C1D15 and C1D22. Accumulation ratios of C<sub>max</sub> and AUC<sub>(0–24 h)</sub> were also calculated for phase 1 by dividing the values on C1D15 by those on C1D1. For the food-effect cohort of phase 2, a mixed-effect model analysis was performed on the natural logarithm transformed C<sub>max</sub> and AUC<sub>(0–24 h)</sub> to assess the effect of a high-fat meal on H3B-6545 PK. In the model, treatment (“fasted” or “fed”), period, and sequence were included as fixed effects and patient nested in sequence was included as a random effect. The geometric least squares (LS) mean ratios (fed/fasted) of the back-transformed C<sub>max</sub> and AUC<sub>(0–24 h)</sub>, and its 90% confidence intervals were calculated. Phoenix WinNonlin version 8.4 (Certara USA, Inc., Princeton, New Jersey) was used for the PK analyses.</p></section></section><section id="Sec7"><h2 class="pmc_sec_title">Results</h2>
<section id="Sec8"><h3 class="pmc_sec_title">Patients and exposure</h3>
<p id="Par17">In total, 151 female patients (47 in phase 1 and 104 in phase 2) were treated within the study. In the total population (across phases 1 and 2), 3 (2.0%) patients remained on treatment at the time of data cutoff (November 30, 2022). All patients in phase 1 and the majority of patients in phase 2 (96.2%) discontinued treatment, primarily due to disease progression (76.6% in phase 1 and 80.8% in phase 2). Patient disposition as of the data cutoff date (November 30, 2022) is shown in Additional file 1 Fig. <a href="#MOESM1" class="usa-link">A2</a>. The median duration of study treatment across both phases was 2.89 months (range, 0.2, 33.1). The median dose intensity per patient was 427.27 mg/day (range, 97.3, 600.0).</p>
<p id="Par18">Baseline demographic and clinical characteristics for patients in phases 1 and 2 are shown in Table <a href="#Tab1" class="usa-link">1</a>. In the total population, the median age was 61.0 years; most patients were White (84.1%), had an <em>ESR1</em> mutation in their tumor (62.3%), and had measurable disease (93.4%).</p>
<section class="tw xbox font-sm" id="Tab1"><h4 class="obj_head">Table 1.</h4>
<div class="caption p"><p>Baseline demographic and clinical characteristics: phases 1 and 2</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1">Category</th>
<th align="left" colspan="1" rowspan="1">100 mg<br>(<em>n</em> = 6)</th>
<th align="left" colspan="1" rowspan="1">200 mg<br>(<em>n</em> = 12)</th>
<th align="left" colspan="1" rowspan="1">300 mg<br>(<em>n</em> = 11)</th>
<th align="left" colspan="1" rowspan="1">450 mg<br>Before PA6<br>(<em>n</em> = 94)</th>
<th align="left" colspan="1" rowspan="1">450 mg Total<br>(<em>n</em> = 115)</th>
<th align="left" colspan="1" rowspan="1">600 mg<br>(<em>n</em> = 7)</th>
<th align="left" colspan="1" rowspan="1">Total<br>(<em>N</em> = 151)</th>
</tr></thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Median age (range), yrs</td>
<td align="left" colspan="1" rowspan="1">65.5 (62, 77)</td>
<td align="left" colspan="1" rowspan="1">51.0 (41, 81)</td>
<td align="left" colspan="1" rowspan="1">57.0 (31, 75)</td>
<td align="left" colspan="1" rowspan="1">61.5 (38, 87)</td>
<td align="left" colspan="1" rowspan="1">61.0 (38, 87)</td>
<td align="left" colspan="1" rowspan="1">65.0 (33, 80)</td>
<td align="center" colspan="1" rowspan="1">61.0 (31, 87)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Race, No. (%)</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> White</td>
<td align="left" colspan="1" rowspan="1">6 (100)</td>
<td align="left" colspan="1" rowspan="1">9 (75.0)</td>
<td align="left" colspan="1" rowspan="1">10 (90.9)</td>
<td align="left" colspan="1" rowspan="1">81 (86.2)</td>
<td align="left" colspan="1" rowspan="1">95 (82.6)</td>
<td align="left" colspan="1" rowspan="1">7 (100)</td>
<td align="center" colspan="1" rowspan="1">127 (84.1)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<p> Black or</p>
<p> African</p>
<p> American</p>
</td>
<td align="left" colspan="1" rowspan="1">0</td>
<td align="left" colspan="1" rowspan="1">1 (8.3)</td>
<td align="left" colspan="1" rowspan="1">1 (9.1)</td>
<td align="left" colspan="1" rowspan="1">5 (5.3)</td>
<td align="left" colspan="1" rowspan="1">5 (4.3)</td>
<td align="left" colspan="1" rowspan="1">0</td>
<td align="center" colspan="1" rowspan="1">7 (4.6)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Asian</td>
<td align="left" colspan="1" rowspan="1">0</td>
<td align="left" colspan="1" rowspan="1">0</td>
<td align="left" colspan="1" rowspan="1">0</td>
<td align="left" colspan="1" rowspan="1">2 (2.1)</td>
<td align="left" colspan="1" rowspan="1">3 (2.6)</td>
<td align="left" colspan="1" rowspan="1">0</td>
<td align="center" colspan="1" rowspan="1">3 (2.0)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Other</td>
<td align="left" colspan="1" rowspan="1">0</td>
<td align="left" colspan="1" rowspan="1">2 (16.7)</td>
<td align="left" colspan="1" rowspan="1">0</td>
<td align="left" colspan="1" rowspan="1">5 (5.3)</td>
<td align="left" colspan="1" rowspan="1">5 (4.3)</td>
<td align="left" colspan="1" rowspan="1">0</td>
<td align="center" colspan="1" rowspan="1">7 (4.6)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Missing</td>
<td align="left" colspan="1" rowspan="1">0</td>
<td align="left" colspan="1" rowspan="1">0</td>
<td align="left" colspan="1" rowspan="1">0</td>
<td align="left" colspan="1" rowspan="1">1 (1.1)</td>
<td align="left" colspan="1" rowspan="1">7 (6.1)</td>
<td align="left" colspan="1" rowspan="1">0</td>
<td align="center" colspan="1" rowspan="1">7 (4.6)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Median weight (range), kg</td>
<td align="left" colspan="1" rowspan="1">
<p>65.00 </p>
<p>(55.9, 83.0)</p>
</td>
<td align="left" colspan="1" rowspan="1">
<p>71.15 </p>
<p>(50.8, 77.3)</p>
</td>
<td align="left" colspan="1" rowspan="1">
<p>81.60 </p>
<p>(47.7, 114.5)</p>
</td>
<td align="left" colspan="1" rowspan="1">
<p>68.80 </p>
<p>(46.3, 140.1)</p>
</td>
<td align="left" colspan="1" rowspan="1">
<p>68.80 </p>
<p>(46.3, 140.1)</p>
</td>
<td align="left" colspan="1" rowspan="1">
<p>69.90 </p>
<p>(59.6, 96.5)</p>
</td>
<td align="center" colspan="1" rowspan="1">
<p>69.40 </p>
<p>(46.3, 140.1)</p>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">ECOG PS, No. (%)</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> 0</td>
<td align="left" colspan="1" rowspan="1">3 (50.0)</td>
<td align="left" colspan="1" rowspan="1">6 (50.0)</td>
<td align="left" colspan="1" rowspan="1">5 (45.5)</td>
<td align="left" colspan="1" rowspan="1">47 (50.0)</td>
<td align="left" colspan="1" rowspan="1">58 (50.4)</td>
<td align="left" colspan="1" rowspan="1">0</td>
<td align="center" colspan="1" rowspan="1">72 (47.7)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> 1</td>
<td align="left" colspan="1" rowspan="1">3 (50.0)</td>
<td align="left" colspan="1" rowspan="1">6 (50.0)</td>
<td align="left" colspan="1" rowspan="1">6 (54.5)</td>
<td align="left" colspan="1" rowspan="1">47 (50.0)</td>
<td align="left" colspan="1" rowspan="1">57 (49.6)</td>
<td align="left" colspan="1" rowspan="1">7 (100)</td>
<td align="center" colspan="1" rowspan="1">79 (52.3)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Measurable disease,<sup>a</sup> No. (%)</td>
<td align="left" colspan="1" rowspan="1">6 (100)</td>
<td align="left" colspan="1" rowspan="1">11 (91.7)</td>
<td align="left" colspan="1" rowspan="1">11 (100)</td>
<td align="left" colspan="1" rowspan="1">85 (90.4)</td>
<td align="left" colspan="1" rowspan="1">106 (92.2)</td>
<td align="left" colspan="1" rowspan="1">7 (100)</td>
<td align="center" colspan="1" rowspan="1">141 (93.4)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Nonmeasurable bone disease only,<sup>b</sup> No. (%)</td>
<td align="left" colspan="1" rowspan="1">0</td>
<td align="left" colspan="1" rowspan="1">1 (8.3)</td>
<td align="left" colspan="1" rowspan="1">0</td>
<td align="left" colspan="1" rowspan="1">9 (9.6)</td>
<td align="left" colspan="1" rowspan="1">9 (7.8)</td>
<td align="left" colspan="1" rowspan="1">0</td>
<td align="center" colspan="1" rowspan="1">10 (6.6)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Site of metastasis, No. (%)</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Brain</td>
<td align="left" colspan="1" rowspan="1">0</td>
<td align="left" colspan="1" rowspan="1">0</td>
<td align="left" colspan="1" rowspan="1">1 (9.1)</td>
<td align="left" colspan="1" rowspan="1">1 (1.1)</td>
<td align="left" colspan="1" rowspan="1">1 (0.9)</td>
<td align="left" colspan="1" rowspan="1">0</td>
<td align="center" colspan="1" rowspan="1">2 (1.3)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Bone</td>
<td align="left" colspan="1" rowspan="1">6 (100)</td>
<td align="left" colspan="1" rowspan="1">9 (75.0)</td>
<td align="left" colspan="1" rowspan="1">8 (72.7)</td>
<td align="left" colspan="1" rowspan="1">74 (78.7)</td>
<td align="left" colspan="1" rowspan="1">91 (79.1)</td>
<td align="left" colspan="1" rowspan="1">6 (85.7)</td>
<td align="center" colspan="1" rowspan="1">120 (79.5)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Breast</td>
<td align="left" colspan="1" rowspan="1">2 (33.3)</td>
<td align="left" colspan="1" rowspan="1">4 (33.3)</td>
<td align="left" colspan="1" rowspan="1">2 (18.2)</td>
<td align="left" colspan="1" rowspan="1">11 (11.7)</td>
<td align="left" colspan="1" rowspan="1">14 (12.2)</td>
<td align="left" colspan="1" rowspan="1">1 (14.3)</td>
<td align="center" colspan="1" rowspan="1">23 (15.2)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Liver</td>
<td align="left" colspan="1" rowspan="1">5 (83.3)</td>
<td align="left" colspan="1" rowspan="1">7 (58.3)</td>
<td align="left" colspan="1" rowspan="1">9 (81.8)</td>
<td align="left" colspan="1" rowspan="1">60 (63.8)</td>
<td align="left" colspan="1" rowspan="1">72 (62.6)</td>
<td align="left" colspan="1" rowspan="1">5 (71.4)</td>
<td align="center" colspan="1" rowspan="1">98 (64.9)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Lung</td>
<td align="left" colspan="1" rowspan="1">1 (16.7)</td>
<td align="left" colspan="1" rowspan="1">2 (16.7)</td>
<td align="left" colspan="1" rowspan="1">6 (54.5)</td>
<td align="left" colspan="1" rowspan="1">39 (41.5)</td>
<td align="left" colspan="1" rowspan="1">45 (39.1)</td>
<td align="left" colspan="1" rowspan="1">2 (28.6)</td>
<td align="center" colspan="1" rowspan="1">56 (37.1)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Kidney</td>
<td align="left" colspan="1" rowspan="1">0</td>
<td align="left" colspan="1" rowspan="1">0</td>
<td align="left" colspan="1" rowspan="1">1 (9.1)</td>
<td align="left" colspan="1" rowspan="1">0</td>
<td align="left" colspan="1" rowspan="1">0</td>
<td align="left" colspan="1" rowspan="1">0</td>
<td align="center" colspan="1" rowspan="1">1 (0.7)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Lymph nodes</td>
<td align="left" colspan="1" rowspan="1">5 (83.3)</td>
<td align="left" colspan="1" rowspan="1">5 (41.7)</td>
<td align="left" colspan="1" rowspan="1">4 (36.4)</td>
<td align="left" colspan="1" rowspan="1">34 (36.2)</td>
<td align="left" colspan="1" rowspan="1">45 (39.1)</td>
<td align="left" colspan="1" rowspan="1">3 (42.9)</td>
<td align="center" colspan="1" rowspan="1">62 (41.1)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Peritoneum/ omentum</td>
<td align="left" colspan="1" rowspan="1">1 (16.7)</td>
<td align="left" colspan="1" rowspan="1">1 (8.3)</td>
<td align="left" colspan="1" rowspan="1">2 (18.2)</td>
<td align="left" colspan="1" rowspan="1">5 (5.3)</td>
<td align="left" colspan="1" rowspan="1">7 (6.1)</td>
<td align="left" colspan="1" rowspan="1">2 (28.6)</td>
<td align="center" colspan="1" rowspan="1">13 (8.6)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Other</td>
<td align="left" colspan="1" rowspan="1">1 (16.7)</td>
<td align="left" colspan="1" rowspan="1">6 (50.0)</td>
<td align="left" colspan="1" rowspan="1">2 (18.2)</td>
<td align="left" colspan="1" rowspan="1">30 (31.9)</td>
<td align="left" colspan="1" rowspan="1">38 (33.0)</td>
<td align="left" colspan="1" rowspan="1">2 (28.6)</td>
<td align="center" colspan="1" rowspan="1">49 (32.5)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<em>ESR1</em> mutation status<sup>c</sup>, No. (%)</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Mutant</td>
<td align="left" colspan="1" rowspan="1">2 (33.3)</td>
<td align="left" colspan="1" rowspan="1">6 (50.0)</td>
<td align="left" colspan="1" rowspan="1">6 (54.5)</td>
<td align="left" colspan="1" rowspan="1">57 (60.6)</td>
<td align="left" colspan="1" rowspan="1">77 (67.0)</td>
<td align="left" colspan="1" rowspan="1">3 (42.9)</td>
<td align="center" colspan="1" rowspan="1">94 (62.3)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Wild-type</td>
<td align="left" colspan="1" rowspan="1">4 (66.7)</td>
<td align="left" colspan="1" rowspan="1">6 (50.0)</td>
<td align="left" colspan="1" rowspan="1">5 (45.5)</td>
<td align="left" colspan="1" rowspan="1">36 (38.3)</td>
<td align="left" colspan="1" rowspan="1">36 (31.3)</td>
<td align="left" colspan="1" rowspan="1">4 (57.1)</td>
<td align="center" colspan="1" rowspan="1">55 (36.4)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Unknown</td>
<td align="left" colspan="1" rowspan="1">0</td>
<td align="left" colspan="1" rowspan="1">0</td>
<td align="left" colspan="1" rowspan="1">0</td>
<td align="left" colspan="1" rowspan="1">1 (1.1)</td>
<td align="left" colspan="1" rowspan="1">2 (1.7)</td>
<td align="left" colspan="1" rowspan="1">0</td>
<td align="center" colspan="1" rowspan="1">2 (1.3)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Number of prior anticancer regimens containing endocrine therapies in locally advanced or metastatic disease settings, median (range)</td>
<td align="left" colspan="1" rowspan="1">3.5 (1, 7)</td>
<td align="left" colspan="1" rowspan="1">3.0 (1, 5)</td>
<td align="left" colspan="1" rowspan="1">2.0 (1, 6)</td>
<td align="left" colspan="1" rowspan="1">2.0 (1, 6)</td>
<td align="left" colspan="1" rowspan="1">2.0 (1, 6)</td>
<td align="left" colspan="1" rowspan="1">2.0 (1, 4)</td>
<td align="center" colspan="1" rowspan="1">2.0 (1, 7)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Number of prior anticancer regimens not containing endocrine therapies in locally advanced or metastatic disease settings, median (range)</td>
<td align="left" colspan="1" rowspan="1">2.0 (1, 3)</td>
<td align="left" colspan="1" rowspan="1">1.0 (1, 3)</td>
<td align="left" colspan="1" rowspan="1">2.0 (1, 4)</td>
<td align="left" colspan="1" rowspan="1">1.0 (1, 6)</td>
<td align="left" colspan="1" rowspan="1">1.0 (1, 6)</td>
<td align="left" colspan="1" rowspan="1">3.0 (1, 5)</td>
<td align="center" colspan="1" rowspan="1">1.0 (1, 6)</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p39">
<p>Abbreviations: AF, allele frequency; ECOG PS, Eastern Cooperative Oncology Group performance status; ESR1, clonal estrogen receptor 1</p>
<p><sup>a</sup>"Measurable disease” is defined as patients having at least 1 target lesion at baseline</p>
<p><sup>b</sup>"Nonmeasurable bone disease only” is defined as patients without measurable disease and with nontarget bone lesions presented at baseline</p>
<p><sup>c</sup><em>ESR1</em> mutation status is defined as: Mutant includes any mutation at an AF ≥ 0.05%; wild-type includes any mutation at an AF &lt; 0.05%. If a patient has more than one allele frequency measurements, the maximum is counted only. Mutant included other <em>ESR1</em> mutations in addition to clonal <em>ESR1</em> Y537S mutation</p>
</div></div></section></section><section id="Sec9"><h3 class="pmc_sec_title">Safety</h3>
<p id="Par20">During phase 1, 2 patients treated at the 600 mg dose level experienced DLTs of grade 3 drug eruption (<em>n</em> = 1) and grade 3 fatigue (<em>n</em> = 1). DLTs were not observed in any other dose groups; thus, 450 mg was deemed both the MTD and the RP2D.</p>
<p id="Par21">An overview of treatment-emergent adverse events (TEAEs) by dose level in phases 1 and 2 is shown in Table <a href="#Tab2" class="usa-link">2</a>. In the total population of patients treated across phases 1 and 2 (safety analysis set), all patients experienced at least 1 TEAE, and 50.3% of patients had grade 3–4 TEAEs. No grade 5 TEAEs were observed, and all deaths were due to disease progression. Serious TEAEs were observed in 23.2% of patients, and serious TEAEs related to study therapy were observed in 4.0% of patients. Any grade and grade 3–4 treatment-related TEAEs were observed in 89.4% and 25.2% of total patients, respectively. TEAEs leading to study drug withdrawal, dose reduction, or interruption occurred in 8.6%, 20.5%, and 38.4% of patients, respectively.</p>
<section class="tw xbox font-sm" id="Tab2"><h4 class="obj_head">Table 2.</h4>
<div class="caption p"><p>Overview of treatment-emergent adverse events by treatment group</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1">Safety parameter, No. (%)</th>
<th align="left" colspan="1" rowspan="1">100 mg<br>(<em>n</em> = 6)</th>
<th align="left" colspan="1" rowspan="1">200 mg<br>(<em>n</em> = 12)</th>
<th align="left" colspan="1" rowspan="1">300 mg<br>(<em>n</em> = 11)</th>
<th align="left" colspan="1" rowspan="1">450 mg<br>(<em>n</em> = 115)</th>
<th align="left" colspan="1" rowspan="1">600 mg<br>(<em>n</em> = 7)</th>
<th align="left" colspan="1" rowspan="1">Total<br>(<em>N</em> = 151)</th>
</tr></thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Any TEAE</td>
<td align="left" colspan="1" rowspan="1">6 (100)</td>
<td align="left" colspan="1" rowspan="1">12 (100)</td>
<td align="left" colspan="1" rowspan="1">11 (100)</td>
<td align="left" colspan="1" rowspan="1">115 (100)</td>
<td align="left" colspan="1" rowspan="1">7 (100)</td>
<td align="left" colspan="1" rowspan="1">151 (100)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Treatment-related TEAE</td>
<td align="left" colspan="1" rowspan="1">3 (50.0)</td>
<td align="left" colspan="1" rowspan="1">8 (66.7)</td>
<td align="left" colspan="1" rowspan="1">9 (81.8)</td>
<td align="left" colspan="1" rowspan="1">108 (93.9)</td>
<td align="left" colspan="1" rowspan="1">7 (100)</td>
<td align="left" colspan="1" rowspan="1">135 (89.4)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Grade 3–4 TEAE</td>
<td align="left" colspan="1" rowspan="1">2 (33.3)</td>
<td align="left" colspan="1" rowspan="1">5 (41.7)</td>
<td align="left" colspan="1" rowspan="1">4 (36.4)</td>
<td align="left" colspan="1" rowspan="1">60 (52.2)</td>
<td align="left" colspan="1" rowspan="1">5 (71.4)</td>
<td align="left" colspan="1" rowspan="1">76 (50.3)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Treatment-related grade 3–4 TEAE</td>
<td align="left" colspan="1" rowspan="1">0 (0)</td>
<td align="left" colspan="1" rowspan="1">2 (16.7)</td>
<td align="left" colspan="1" rowspan="1">0 (0)</td>
<td align="left" colspan="1" rowspan="1">33 (28.7)</td>
<td align="left" colspan="1" rowspan="1">3 (42.9)</td>
<td align="left" colspan="1" rowspan="1">38 (25.2)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Any serious TEAE</td>
<td align="left" colspan="1" rowspan="1">2 (33.3)</td>
<td align="left" colspan="1" rowspan="1">1 (8.3)</td>
<td align="left" colspan="1" rowspan="1">2 (18.2)</td>
<td align="left" colspan="1" rowspan="1">29 (25.2)</td>
<td align="left" colspan="1" rowspan="1">1 (14.3)</td>
<td align="left" colspan="1" rowspan="1">35 (23.2)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Treatment-related serious TEAE</td>
<td align="left" colspan="1" rowspan="1">0 (0)</td>
<td align="left" colspan="1" rowspan="1">0 (0)</td>
<td align="left" colspan="1" rowspan="1">0 (0)</td>
<td align="left" colspan="1" rowspan="1">5 (4.3)</td>
<td align="left" colspan="1" rowspan="1">1 (14.3)</td>
<td align="left" colspan="1" rowspan="1">6 (4.0)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">TEAEs leading to study drug:</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Withdrawal</td>
<td align="left" colspan="1" rowspan="1">0 (0)</td>
<td align="left" colspan="1" rowspan="1">0 (0)</td>
<td align="left" colspan="1" rowspan="1">0 (0)</td>
<td align="left" colspan="1" rowspan="1">11 (9.6)</td>
<td align="left" colspan="1" rowspan="1">2 (28.6)</td>
<td align="left" colspan="1" rowspan="1">13 (8.6)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Dose reduction</td>
<td align="left" colspan="1" rowspan="1">0 (0)</td>
<td align="left" colspan="1" rowspan="1">0 (0)</td>
<td align="left" colspan="1" rowspan="1">0 (0)</td>
<td align="left" colspan="1" rowspan="1">30 (26.1)</td>
<td align="left" colspan="1" rowspan="1">1 (14.3)</td>
<td align="left" colspan="1" rowspan="1">31 (20.5)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Interruption</td>
<td align="left" colspan="1" rowspan="1">1 (16.7)</td>
<td align="left" colspan="1" rowspan="1">4 (33.3)</td>
<td align="left" colspan="1" rowspan="1">2 (18.2)</td>
<td align="left" colspan="1" rowspan="1">46 (40.0)</td>
<td align="left" colspan="1" rowspan="1">5 (71.4)</td>
<td align="left" colspan="1" rowspan="1">58 (38.4)</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p47">
<p>Abbreviation: TEAE, treatment-emergent adverse event</p>
<p>No grade 5 TEAEs were observed. TEAEs with preferred terms of “Neoplasm progression,” “Malignant neoplasm progression,” and “Disease progression” not related to the drug are excluded. For each category, a patient with 2 or more adverse events in that category is counted only once. A patient may be counted in multiple categories</p>
</div></div></section><p id="Par23">The most frequent any-grade TEAEs (≥ 40% of patients) were nausea (46%), sinus bradycardia (44%), and diarrhea (41%). In the 450 mg cohort (including 11 patients from phase 1 and 104 patients from phase 2), all patients experienced at least 1 TEAE, and 52% of patients had grade 3–4 TEAEs; the most frequent any-grade TEAEs (≥ 40% of patients) in the 450 mg cohort were nausea (48%), diarrhea (47%), and sinus bradycardia (45%) (Table <a href="#Tab3" class="usa-link">3</a>).</p>
<section class="tw xbox font-sm" id="Tab3"><h4 class="obj_head">Table 3.</h4>
<div class="caption p"><p>Frequently occurring TEAEs (≥ 20% of total patients)</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" rowspan="2" colspan="1">MedDRA PT, No. (%)</th>
<th align="left" colspan="2" rowspan="1">100 mg<br>(<em>n</em> = 6)</th>
<th align="left" colspan="2" rowspan="1">200 mg<br>(<em>n</em> = 12)</th>
<th align="left" colspan="2" rowspan="1">300 mg<br>(<em>n</em> = 11)</th>
<th align="left" colspan="2" rowspan="1">450 mg<br>(<em>n</em> = 115)</th>
<th align="left" colspan="2" rowspan="1">600 mg<br>(<em>n</em> = 7)</th>
<th align="left" colspan="2" rowspan="1">Total<br>(<em>N</em> = 151)</th>
</tr>
<tr>
<th align="left" colspan="1" rowspan="1">Any</th>
<th align="left" colspan="1" rowspan="1">G3–4</th>
<th align="left" colspan="1" rowspan="1">Any</th>
<th align="left" colspan="1" rowspan="1">G3–4</th>
<th align="left" colspan="1" rowspan="1">Any</th>
<th align="left" colspan="1" rowspan="1">G3–4</th>
<th align="left" colspan="1" rowspan="1">Any</th>
<th align="left" colspan="1" rowspan="1">G3–4</th>
<th align="left" colspan="1" rowspan="1">Any</th>
<th align="left" colspan="1" rowspan="1">G3–4</th>
<th align="left" colspan="1" rowspan="1">Any</th>
<th align="left" colspan="1" rowspan="1">G3–4</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Nausea</td>
<td align="left" colspan="1" rowspan="1">2 (33.3)</td>
<td align="left" colspan="1" rowspan="1">0</td>
<td align="center" colspan="1" rowspan="1">4 (33.3)</td>
<td align="left" colspan="1" rowspan="1">0</td>
<td align="center" colspan="1" rowspan="1">4 (36.4)</td>
<td align="center" colspan="1" rowspan="1">0</td>
<td align="center" colspan="1" rowspan="1">55 (47.8)</td>
<td align="left" colspan="1" rowspan="1">4 (3.5)</td>
<td align="center" colspan="1" rowspan="1">4 (57.1)</td>
<td align="left" colspan="1" rowspan="1">0</td>
<td align="center" colspan="1" rowspan="1">69 (45.7)</td>
<td align="left" colspan="1" rowspan="1">4 (2.6)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Sinus bradycardia</td>
<td align="left" colspan="1" rowspan="1">0</td>
<td align="left" colspan="1" rowspan="1">0</td>
<td align="center" colspan="1" rowspan="1">6 (50.0)</td>
<td align="left" colspan="1" rowspan="1">0</td>
<td align="center" colspan="1" rowspan="1">8 (72.7)</td>
<td align="center" colspan="1" rowspan="1">0</td>
<td align="center" colspan="1" rowspan="1">52 (45.2)</td>
<td align="left" colspan="1" rowspan="1">0</td>
<td align="center" colspan="1" rowspan="1">1 (14.3)</td>
<td align="left" colspan="1" rowspan="1">0</td>
<td align="center" colspan="1" rowspan="1">67 (44.4)</td>
<td align="left" colspan="1" rowspan="1">0</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Diarrhea</td>
<td align="left" colspan="1" rowspan="1">2 (33.3)</td>
<td align="left" colspan="1" rowspan="1">0</td>
<td align="center" colspan="1" rowspan="1">2 (16.7)</td>
<td align="left" colspan="1" rowspan="1">0</td>
<td align="center" colspan="1" rowspan="1">3 (27.3)</td>
<td align="center" colspan="1" rowspan="1">0</td>
<td align="center" colspan="1" rowspan="1">54 (47.0)</td>
<td align="left" colspan="1" rowspan="1">5 (4.3)</td>
<td align="center" colspan="1" rowspan="1">1 (14.3)</td>
<td align="left" colspan="1" rowspan="1">0</td>
<td align="center" colspan="1" rowspan="1">62 (41.1)</td>
<td align="left" colspan="1" rowspan="1">5 (3.3)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Anemia</td>
<td align="left" colspan="1" rowspan="1">3 (50.0)</td>
<td align="left" colspan="1" rowspan="1">1 (16.7)</td>
<td align="center" colspan="1" rowspan="1">4 (33.3)</td>
<td align="left" colspan="1" rowspan="1">1 (8.3)</td>
<td align="center" colspan="1" rowspan="1">5 (45.5)</td>
<td align="center" colspan="1" rowspan="1">0</td>
<td align="center" colspan="1" rowspan="1">39 (33.9)</td>
<td align="left" colspan="1" rowspan="1">13 (11.3)</td>
<td align="center" colspan="1" rowspan="1">4 (57.1)</td>
<td align="left" colspan="1" rowspan="1">3 (42.9)</td>
<td align="center" colspan="1" rowspan="1">55 (36.4)</td>
<td align="left" colspan="1" rowspan="1">18 (11.9)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Fatigue</td>
<td align="left" colspan="1" rowspan="1">2 (33.3)</td>
<td align="left" colspan="1" rowspan="1">0</td>
<td align="center" colspan="1" rowspan="1">4 (33.3)</td>
<td align="left" colspan="1" rowspan="1">0</td>
<td align="center" colspan="1" rowspan="1">3 (27.3)</td>
<td align="center" colspan="1" rowspan="1">0</td>
<td align="center" colspan="1" rowspan="1">42 (36.5)</td>
<td align="left" colspan="1" rowspan="1">8 (7.0)</td>
<td align="center" colspan="1" rowspan="1">2 (28.6)</td>
<td align="left" colspan="1" rowspan="1">2 (28.6)</td>
<td align="center" colspan="1" rowspan="1">53 (35.1)</td>
<td align="left" colspan="1" rowspan="1">10 (6.6)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Vomiting</td>
<td align="left" colspan="1" rowspan="1">3 (50.0)</td>
<td align="left" colspan="1" rowspan="1">0</td>
<td align="center" colspan="1" rowspan="1">2 (16.7)</td>
<td align="left" colspan="1" rowspan="1">0</td>
<td align="center" colspan="1" rowspan="1">2 (18.2)</td>
<td align="center" colspan="1" rowspan="1">0</td>
<td align="center" colspan="1" rowspan="1">30 (26.1)</td>
<td align="left" colspan="1" rowspan="1">4 (3.5)</td>
<td align="center" colspan="1" rowspan="1">2 (28.6)</td>
<td align="left" colspan="1" rowspan="1">0</td>
<td align="center" colspan="1" rowspan="1">39 (25.8)</td>
<td align="left" colspan="1" rowspan="1">4 (2.6)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">AST</td>
<td align="left" colspan="1" rowspan="1">2 (33.3)</td>
<td align="left" colspan="1" rowspan="1">1 (16.7)</td>
<td align="center" colspan="1" rowspan="1">5 (41.7)</td>
<td align="left" colspan="1" rowspan="1">2 (16.7)</td>
<td align="center" colspan="1" rowspan="1">3 (27.3)</td>
<td align="center" colspan="1" rowspan="1">0</td>
<td align="center" colspan="1" rowspan="1">18 (15.7)</td>
<td align="left" colspan="1" rowspan="1">3 (2.6)</td>
<td align="center" colspan="1" rowspan="1">4 (57.1)</td>
<td align="left" colspan="1" rowspan="1">2 (28.6)</td>
<td align="center" colspan="1" rowspan="1">32 (21.2)</td>
<td align="left" colspan="1" rowspan="1">8 (5.3)</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p52"><p>Abbreviations: AST, aspartate aminotransferase increased; G, grade; MedDRA, Medical Dictionary for Regulatory Activities; PT, preferred term; TEAE, treatment-emergent adverse event</p></div></div></section><p id="Par25">Adverse events of special interest (AESI) are listed by cohort in Additional file 1 Table <a href="#MOESM1" class="usa-link">A1</a>. Across all dose groups (<em>N</em> = 151), notable AESI included bradycardia (<em>n</em> = 71; 47.0%), rash (<em>n</em> = 23; 15.2%) and QT prolongation (<em>n</em> = 15; 9.9%). Sinus bradycardia in particular was reported in 67 (44.4%) patients. Five (3.3%) patients, all in the 450 mg dose group, experienced grade ≥ 3 QT prolongation, and one QT prolongation event was considered serious. No sinus bradycardia events were grade ≥ 3 or serious, irrespective of dose group. Treatment was interrupted in 2 (1.3%) patients due to sinus bradycardia (450 mg dose group), 3 (2.0%) patients due to rash maculopapular (450 mg dose group), and in 2 (1.3%) patients due to QT prolongation (450 mg dose group). Dose reduction due to QT prolongation, sinus bradycardia and rash occurred in 3 (2.0%), 8 (5.3%) and 1 (0.7%) patient(s), respectively, across dose groups. Treatment was discontinued in 2 (1.3%) patients each due to QT prolongations (450 mg dose group) or rash maculopapular (450 mg dose group). Bradycardia and sinus bradycardia did not lead to treatment discontinuation in any patient, irrespective of dose group.</p></section><section id="Sec10"><h3 class="pmc_sec_title">Efficacy</h3>
<p id="Par26">In phase 1, partial response was achieved in 3 patients, 1 from each of the 100 mg, 200 mg, and 450 mg dose cohorts. Tumor responses in response-evaluable patients treated at 450 mg (including subsets of patients treated before/after PA6 and those with clonal <em>ESR1</em> Y537S mutations) are summarized in Table <a href="#Tab4" class="usa-link">4</a>. The ORR in all response-evaluable patients treated at 450 mg (<em>n</em> = 94, including 8 patients from phase 1) was 20.2% (95% CI 12.6–29.8). The median duration of response was 9.23 months (95% CI 5.88–20.24). The clinical benefit rate was 41.5% (95% CI 31.4–52.1). Patients treated at 450 mg before (<em>n</em> = 73) and on/after PA6 (<em>n</em> = 21) had ORRs of 16.4% (95% CI 8.8–27.0) and 33.3% (95% CI 14.6–57.0), respectively, and CBRs of 38.4% (95% CI 27.2–50.5) and 52.4% (95% CI 29.8–74.3), respectively. Patients with clonal <em>ESR1</em> Y537S mutation had an ORR of 32.1% (95% CI 15.9–52.4) and a CBR of 57.1% (95% CI 37.2–75.5).</p>
<section class="tw xbox font-sm" id="Tab4"><h4 class="obj_head">Table 4.</h4>
<div class="caption p"><p>Tumor responses in response-evaluable patients treated at 450 mg</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1"></th>
<th align="left" colspan="1" rowspan="1">450 mg before PA6<br>(<em>n</em> = 73)</th>
<th align="left" colspan="1" rowspan="1">450 mg on/after PA6<br>(<em>n</em> = 21)</th>
<th align="left" colspan="1" rowspan="1">Clonal Y537S<br>(<em>n</em> = 28)</th>
<th align="left" colspan="1" rowspan="1">Total 450 mg<br>(<em>n</em> = 94)</th>
</tr></thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">BOR, %</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> CR</td>
<td align="left" colspan="1" rowspan="1">0</td>
<td align="left" colspan="1" rowspan="1">0</td>
<td align="left" colspan="1" rowspan="1">0</td>
<td align="left" colspan="1" rowspan="1">0</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> PR</td>
<td align="left" colspan="1" rowspan="1">16.4</td>
<td align="left" colspan="1" rowspan="1">33.3</td>
<td align="left" colspan="1" rowspan="1">32.1</td>
<td align="left" colspan="1" rowspan="1">20.2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> SD</td>
<td align="left" colspan="1" rowspan="1">42.5</td>
<td align="left" colspan="1" rowspan="1">38.1</td>
<td align="left" colspan="1" rowspan="1">39.3</td>
<td align="left" colspan="1" rowspan="1">41.5</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> PD</td>
<td align="left" colspan="1" rowspan="1">38.4</td>
<td align="left" colspan="1" rowspan="1">23.8</td>
<td align="left" colspan="1" rowspan="1">25.0</td>
<td align="left" colspan="1" rowspan="1">35.1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Not evaluable</td>
<td align="left" colspan="1" rowspan="1">2.7</td>
<td align="left" colspan="1" rowspan="1">4.8</td>
<td align="left" colspan="1" rowspan="1">3.6</td>
<td align="left" colspan="1" rowspan="1">3.2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">ORR (CR + PR), % (95% CI)<sup>a</sup>
</td>
<td align="left" colspan="1" rowspan="1">16.4 (8.8, 27.0)</td>
<td align="left" colspan="1" rowspan="1">33.3 (14.6, 57.0)<sup>b</sup>
</td>
<td align="left" colspan="1" rowspan="1">32.1 (15.9, 52.4)</td>
<td align="left" colspan="1" rowspan="1">20.2 (12.6, 29.8)<sup>b</sup>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">DCR<sup>c</sup>, % (95% CI)<sup>a</sup>
</td>
<td align="left" colspan="1" rowspan="1">58.9 (46.8, 70.3)</td>
<td align="left" colspan="1" rowspan="1">71.4 (47.8, 88.7)</td>
<td align="left" colspan="1" rowspan="1">71.4 (51.3, 86.8)</td>
<td align="left" colspan="1" rowspan="1">61.7 (51.1, 71.5)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CBR<sup>d</sup>, % (95% CI)<sup>a</sup>
</td>
<td align="left" colspan="1" rowspan="1">38.4 (27.2, 50.5)</td>
<td align="left" colspan="1" rowspan="1">52.4 (29.8, 74.3)</td>
<td align="left" colspan="1" rowspan="1">57.1 (37.2, 75.5)</td>
<td align="left" colspan="1" rowspan="1">41.5 (31.4, 52.1)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">DOR<sup>e</sup>, months, median (95% CI)</td>
<td align="left" colspan="1" rowspan="1">12.91 (5.39, NE)</td>
<td align="left" colspan="1" rowspan="1">9.18 (5.59, NE)</td>
<td align="left" colspan="1" rowspan="1">9.13 (5.39, NE)</td>
<td align="left" colspan="1" rowspan="1">9.23 (5.88, 20.24)</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab4/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p57">
<p>Abbreviations: BOR, best overall response; CBR, clinical benefit rate; CDK4/6, cyclin-dependent kinase 4/6; CI, confidence interval; CR, complete response; DCR, disease control rate; DOR, duration of response; ESR1, estrogen receptor 1; NE, not estimable or not evaluable; ORR, objective response rate; PA6, protocol amendment 6; PD, progressive disease; PR, partial response, RECIST v1.1, Response Evaluation Criteria in Solid Tumors version 1.1; SD, stable disease</p>
<p>Patients on/after PA6 must have had prior CDK4/6-inhibitor therapy, measurable disease, and <em>ESR1</em> Y537S mutation in the absence of <em>ESR1</em> D538G mutation. Response-evaluable patients included those who received at least 1 dose of study drug and had measurable disease at baseline, and at least 1 postbaseline evaluation. Of 94 patients treated at 450 mg before PA6, 85 had measurable disease, and 73 were included into the response-evaluable patient population by the above definition. After PA6, all patients were included in this population. Responses were assessed by the investigator per RECIST v1.1 criteria</p>
<p><sup>a</sup>Constructed using the method of Clopper-Pearson, in a 2-sided exact manner; <sup>b</sup>1-sided <em>P</em> value ≤ 0.0001 (from the exact binomial test under the null hypothesis of ORR = 5%); <sup>c</sup>DCR = CR + PR + SD (achieved at least ≥ 7 weeks after the first dose); <sup>d</sup>CBR = CR + PR + durable SD (SD with duration ≥ 23 weeks). <sup>e</sup>DOR is reported for patients with an objective response (450 mg before PA6, <em>n</em> = 12; 450 mg on/after PA6, <em>n</em> = 7; clonal Y537S, <em>n</em> = 9; 450 mg, <em>n</em> = 19)</p>
</div></div></section><p id="Par28">PFS and OS in patients treated at 450 mg who received at least 1 dose of the study drug (total patients treated at 450 mg [<em>n</em> = 115] and the subset of patients with clonal <em>ESR1</em> Y537S mutation treated at 450 mg [<em>n</em> = 28]) are shown in Fig. <a href="#Fig1" class="usa-link">1</a>. The median follow-up time for PFS was 14.5 months (95% CI 11.0–16.5). Median PFS was 4.6 months (95% CI 3.5–6.7) for all patients who received H3B-6545 450 mg and 7.3 months (95% CI 3.1–11.1) for patients with clonal <em>ESR1</em> Y537S mutations. The median follow-up time for OS was 36.4 months (95% CI: 35.1–38.3). The median OS in patients treated at 450 mg who received at least 1 dose of the study drug was 21.5 months (95% CI 16.6–25.5). Overall survival rates at 6 and 12 months were 84.6% (95% CI: 76.4–90.1) and 71.3% (95% CI 61.8–78.9), respectively. For patients with clonal <em>ESR1</em> Y537S mutation, the median OS was 18.6 months (95% CI 10.9–not estimable). PFS and OS in patients per dose group are shown in Additional file 1 Fig. <a href="#MOESM1" class="usa-link">A3</a>.</p>
<figure class="fig xbox font-sm" id="Fig1"><h4 class="obj_head">Fig. 1.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12363031_13058_2025_2069_Fig1_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7b0/12363031/c65b5e15fe3e/13058_2025_2069_Fig1_HTML.jpg" loading="lazy" id="d33e2006" height="1015" width="744" alt="Fig. 1"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>PFS (<strong>A</strong>) and OS (<strong>B</strong>) in total patients and patients with clonal Y537S mutation, and change in size of target lesions by <em>ESR1</em> mutation subtypes, in patients treated at 450 mg (<strong>C</strong>) CI, confidence interval; ESR1, estrogen receptor 1 gene; mos, months; OS, overall survival; PFS, progression-free survival; RECIST v1.1, Response Evaluation Criteria in Solid Tumors version 1.1</p></figcaption></figure><p id="Par30">The efficacy by key subgroups in all patients treated at the 450 mg dose level is shown in Additional file 1 Table <a href="#MOESM1" class="usa-link">A2</a>. Antitumor activity was generally observed irrespective of prior treatment (type or number of therapies) and baseline tumor characteristics subgroups. Notably, in patients with <em>ESR1</em> clonal Y537S mutations, ORR was 32.1% (95% CI 15.9–52.4).</p></section><section id="Sec11"><h3 class="pmc_sec_title">Pharmacokinetics</h3>
<p id="Par31">Plasma H3B-6545 concentration-time profiles of phase 1 are shown in Fig. <a href="#Fig2" class="usa-link">2</a>. PK parameters of phase 1 are shown in Additional file 1 Table <a href="#MOESM1" class="usa-link">A3</a>. Plasma H3B-6545 concentrations reached C<sub>max</sub> around 2–4 h postdose and showed a mono-exponential decline. PK parameters (C<sub>max</sub> and AUC<sub>(0–24 h)</sub>) increased with increasing doses, and especially increased more than dose-proportionally after a single dose on C1D1. Accumulation ratios of C<sub>max</sub> and AUC<sub>(0–24 h)</sub> were less than 2 for all dose levels, indicating only slight accumulation after multiple administrations. Plasma concentration-time profiles of the food-effect cohort of phase 2 are shown in Additional file 1 Fig. <a href="#MOESM1" class="usa-link">A4</a>. PK parameters and statistical analysis results to assess the food effect are shown in Additional file 1 Table <a href="#MOESM1" class="usa-link">A4</a> and Table <a href="#MOESM1" class="usa-link">A5</a>, respectively. The geometric mean ratios of C<sub>max</sub> and AUC<sub>(0–24 h)</sub> showed that the H3B-6545 exposures were 51% and 53% higher, respectively, under fed conditions with high-fat meal than fasted conditions. The median t<sub>max</sub> was 6 h under fed conditions and 4 h under fasted conditions. The absorption of H3B-6545 appeared to be delayed under fed conditions.</p>
<figure class="fig xbox font-sm" id="Fig2"><h4 class="obj_head">Fig. 2.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12363031_13058_2025_2069_Fig2_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a7b0/12363031/1ebfd21cf290/13058_2025_2069_Fig2_HTML.jpg" loading="lazy" id="d33e2068" height="312" width="669" alt="Fig. 2"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Semilogarithmic plots of mean (+ SD) plasma H3B-6545 concentration in patients treated in phase 1 (cycle 1 day 1 <strong>a</strong> and cycle 1 day 15 <strong>b</strong>). h, hours; QD, once daily; SD, standard deviation</p></figcaption></figure></section></section><section id="Sec12"><h2 class="pmc_sec_title">Discussion</h2>
<p id="Par33">Existing ER-directed therapies, including the SERDs elacestrant [<a href="#CR3" class="usa-link" aria-describedby="CR3">3</a>] and imlunestrant [<a href="#CR12" class="usa-link" aria-describedby="CR12">12</a>], have demonstrated efficacy in patients with ER-positive BC. However, resistance to SERDs and other ER-directed therapies is a major challenge to durable treatment response, particularly in patients with <em>ESR1</em> gene mutations [<a href="#CR5" class="usa-link" aria-describedby="CR5">5</a>, <a href="#CR15" class="usa-link" aria-describedby="CR15">15</a>]. SERCAs, including H3B-6545, have recently been introduced in an effort to support this unmet treatment need [<a href="#CR15" class="usa-link" aria-describedby="CR15">15</a>, <a href="#CR18" class="usa-link" aria-describedby="CR18">18</a>].</p>
<p id="Par34">In the present study, H3B-6545 was tolerable and had a manageable safety profile at doses up to 450 mg QD in this first-in-human study of women with advanced or metastatic ER+, HER2 − BC, as evidenced by low dose reduction (26.1%) and discontinuation (9.6%) rates in patients who received the 450 mg dose. Additionally, a low rate of grade ≥ 3 TEAEs related to study therapy was observed, with no DLTs with dosages &lt; 600 mg QD. Although sinus bradycardia, QT prolongation, and rash were observed, the associated rates of study drug discontinuation were very low. Sinus bradycardia and QT prolongation were reported as a TEAE in 67 (44.4%) and 15 (9.9%) patients across dose groups. None of the sinus bradycardia were grade ≥ 3 or serious. Five (3.3%) patients experienced grade ≥ 3 QT prolongation and 1 experienced an event of QT prolongation that was considered serious, both in the 450 mg dose group. Sinus bradycardia did not lead to study drug discontinuation. QT prolongation led to study drug discontinuation in 2 (1.3%) patients in the 450 mg dose group. Sinus bradycardia led to dose reduction in 8 (5.3%) patients (across dose groups) and dose interruption in 2 (1.3%) patients, both in the 450 mg dose group. QT prolongation led to dose reduction in 3 (2.0%) patients (across dose groups) and dose interruption in 2 (1.3%) patients, both in the 450 mg dose group. These events were carefully monitored and generally manageable with dose modification for continuous anticancer treatment.</p>
<p id="Par35">H3B-6545 showed promising antitumor activity in pretreated female patients with ER+, HER2 − BC, including in patients with <em>ESR1</em> clonal Y537S mutation, which is notable given that this mutation has been associated with more aggressive disease [<a href="#CR6" class="usa-link" aria-describedby="CR6">6</a>]. Median PFS was 4.60 months among all patients who received 450 mg and 7.33 months in those with <em>ESR1</em> clonal mutations. It should be noted the <em>ESR1</em> Y537S subgroup sample size was small (<em>n</em> = 28) and therefore further research in a larger population is needed for further confirmation. Partial responses and tumor shrinkage were seen across subgroups, including in patients with <em>ESR1</em> clonal Y537S mutation. The CBR was 41.5% in total patients who received 450 mg and 57.1% in the <em>ESR1</em> clonal Y537S subgroup of patients who received 450 mg. Notably, the antitumor activity of H3B-6545 did not appear to be confounded by fewer prior lines of therapy in patients with clonal <em>ESR1</em> Y537S mutation. In fact, patients who received ≥ 3 prior lines of therapy demonstrated a slightly longer median PFS of 8.87 months compared with those only receiving 2 prior lines (7.52 months), suggesting H3B-6545 retained activity even in heavily pretreated patients. Furthermore, appreciable antitumor activity was observed in patients with ≥ 3 prior lines of therapy, as shown by an ORR of 38.5% and a CBR of 76.9%, indicating that H3B-6545 can exert an effect even in a more refractory disease setting (Additional file 1 Table <a href="#MOESM1" class="usa-link">A2</a>). Overall, antitumor activity was generally observed across dose groups, including in patients with visceral metastases and patients who received prior fulvestrant and/or novel oral SERDs, prior CDK4/6 inhibitors, and/or prior chemotherapy in the metastatic setting. These data highlight a potential advantage of H3B-6545 in the treatment landscape. H3B-6545 may also be further investigated to provide a new oral endocrine therapy option especially for patients with previously treated ER + BC, including <em>ESR1</em>-mutant BC. Additionally, the combination of H3B-6545 300 mg with palbociclib was deemed to be tolerable and showed promising preliminary antitumor activity, indicating potential for combination therapy [<a href="#CR19" class="usa-link" aria-describedby="CR19">19</a>]. Heterogeneous tumor responses were seen across mutation subgroups. In contrast to tumors harboring clonal Y537S mutations, those with clonal D538G mutations exhibited minimal antitumor activity (median PFS 3.55 months, ORR 0.0%), although the CBR was 29.4%. The polyclonal Y537S and D538G subgroup also showed limited activity (median PFS 2.61 months, ORR 0.0%, CBR 33.3%).</p>
<p id="Par36">Due to the limited population size and different populations, comparisons between our study and others (i.e., VERONICA and EMERALD) should be made with caution. However, in heavily pretreated patients, the median PFS of H3B-6545 450 mg in this study (4.6 months) was notable in the context of the median PFS of elacestrant (2.8 months; 3.8 months in the ESR1 subgroup) in EMERALD, and of venetoclax plus fulvestrant/fulvestrant (2.69/1.94 months) in VERONICA [<a href="#CR3" class="usa-link" aria-describedby="CR3">3</a>, <a href="#CR7" class="usa-link" aria-describedby="CR7">7</a>]. H3B-6545 also showed a numerically longer median PFS of 7.33 months in the <em>ESR1</em> Y537S subgroup, compared with the 5.5 months seen with imlunestrant monotherapy in the <em>ESR1</em> population in EMBER-3 [<a href="#CR12" class="usa-link" aria-describedby="CR12">12</a>]. Notably, the imlunestrant/abemaciclib combination in EMBER-3 achieved a PFS of 9.4 months, underscoring the potential of combination strategies. These findings suggest that SERCAs like H3B-6545 hold promise in this challenging landscape, particularly for patients with <em>ESR1</em> mutations.</p>
<p id="Par37">In PK analyses, blood exposure to H3B-6545 increased in a dose-dependent manner, especially more than dose-proportionally after a single dose. Slight accumulation of H3B-6545 was observed after multiple administrations. The high-fat meal, which has the maximum effects on drug absorption, increased blood exposure to H3B-6545 by approximately 50%. Therefore, the food effect on H3B-6545 PK was not considered clinically significant.</p></section><section id="Sec13"><h2 class="pmc_sec_title">Conclusions</h2>
<p id="Par38">In this study, H3B-6545 had a manageable safety profile while showing antitumor activity. Encouraging clinical activity was also observed in patients with <em>ESR1</em> Y537S mutation, which is particularly notable given the link between <em>ESR1</em> mutations and ET resistance shown in extant studies. These results suggest that H3B-6545 may be further investigated to potentially offer a new oral endocrine therapy option for patients with previously treated metastatic hormone receptor-positive BC, including <em>ESR1</em>-mutant BC.</p></section><section id="Sec14"><h2 class="pmc_sec_title">Electronic supplementary material</h2>
<p>Below is the link to the electronic supplementary material.</p>
<section class="sm xbox font-sm" id="MOESM1"><div class="media p"><div class="caption">
<a href="/articles/instance/12363031/bin/13058_2025_2069_MOESM1_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">Supplementary Material 1</a><sup> (871.6KB, docx) </sup>
</div></div></section></section><section id="ack1" class="ack"><h2 class="pmc_sec_title">Acknowledgements</h2>
<p>Medical writing support was provided by Irene Spears, PhD, of Oxford PharmaGenesis Inc. We thank Certara USA, Inc. for their support in PK analysis.</p></section><section id="glossary1" class="glossary"><h2 class="pmc_sec_title">Abbreviations</h2>
<dl class="def-list">
<dt>AF</dt>
<dd><p id="Par43">Allelic frequency</p></dd>
<dt>AUC<sub>(0–24 h)</sub>
</dt>
<dd><p id="Par44">Area under the plasma concentration-time curve from time zero to 24 h postdose</p></dd>
<dt>BC</dt>
<dd><p id="Par45">Breast cancer</p></dd>
<dt>BOR</dt>
<dd><p id="Par46">Best overall response</p></dd>
<dt>C1D1</dt>
<dd><p id="Par47">Cycle 1 day 1</p></dd>
<dt>C1D15</dt>
<dd><p id="Par48">Cycle 1 day 15</p></dd>
<dt>C1D22</dt>
<dd><p id="Par49">Cycle 1 day 22</p></dd>
<dt>CBR</dt>
<dd><p id="Par50">Clinical benefit rate</p></dd>
<dt>CDK4/6</dt>
<dd><p id="Par51">Cyclin-dependent kinase 4/6</p></dd>
<dt>CI</dt>
<dd><p id="Par52">Confidence interval</p></dd>
<dt>C<sub>max</sub>
</dt>
<dd><p id="Par53">Maximum observed plasma concentration</p></dd>
<dt>CR</dt>
<dd><p id="Par54">Complete response</p></dd>
<dt>DLT</dt>
<dd><p id="Par55">Dose-limiting toxicity</p></dd>
<dt>DOR</dt>
<dd><p id="Par56">Duration of response</p></dd>
<dt>ER</dt>
<dd><p id="Par57">Estrogen receptor</p></dd>
<dt>ER + </dt>
<dd><p id="Par58">Estrogen receptor-positive</p></dd>
<dt>ERα </dt>
<dd><p id="Par59">Estrogen receptor alpha</p></dd>
<dt>ETs</dt>
<dd><p id="Par60">Endocrine therapies</p></dd>
<dt>HER2 − </dt>
<dd><p id="Par61">Human epidermal growth factor receptor-negative</p></dd>
<dt>LHRH</dt>
<dd><p id="Par62">Luteinizing hormone-releasing hormone</p></dd>
<dt>LS</dt>
<dd><p id="Par63">Least squares</p></dd>
<dt>MTD</dt>
<dd><p id="Par64">Maximum tolerated dose</p></dd>
<dt>ORR</dt>
<dd><p id="Par65">Objective response rate</p></dd>
<dt>OS</dt>
<dd><p id="Par66">Overall survival</p></dd>
<dt>PA6</dt>
<dd><p id="Par67">Protocol Amendment 6</p></dd>
<dt>PFS</dt>
<dd><p id="Par68">Progression-free survival</p></dd>
<dt>PK</dt>
<dd><p id="Par69">Pharmacokinetics</p></dd>
<dt>PR</dt>
<dd><p id="Par70">Partial response</p></dd>
<dt>QD</dt>
<dd><p id="Par71">Once daily</p></dd>
<dt>RP2D</dt>
<dd><p id="Par72">Recommended phase 2 dose</p></dd>
<dt>SERCA</dt>
<dd><p id="Par73">Selective estrogen receptor covalent antagonist</p></dd>
<dt>SERD</dt>
<dd><p id="Par74">Selective estrogen receptor degrader</p></dd>
<dt>TEAEs</dt>
<dd><p id="Par75">Treatment-emergent adverse events</p></dd>
<dt>t<sub>max</sub>
</dt>
<dd><p id="Par76">Time at which C<sub>max</sub> occurs</p></dd>
</dl></section><section id="notes1"><h2 class="pmc_sec_title">Author contributions</h2>
<p>EH, TP, JSW, AM, SJ, ECD, CV, AA, PM, NU, GSW, FK, TS, YR, KY, DJ: conceptualization, investigation, resources, writing – original draft, writing – review and editing; methodology; KY, TS: data curation, formal analysis. All authors have read and approved the final version of the manuscript.</p></section><section id="notes2"><h2 class="pmc_sec_title">Funding</h2>
<p>The study was sponsored by Eisai Inc, Nutley, NJ, USA. Medical writing support was funded by Eisai Inc., Nutley, NJ, USA.</p></section><section id="notes3"><h2 class="pmc_sec_title">Data availability</h2>
<p>The data will not be available for sharing at this time because the data are commercially confidential. However, Eisai Inc. will consider written requests to share the data on a case-by-case basis.</p></section><section id="notes4"><h2 class="pmc_sec_title">Declarations</h2>
<section id="FPar1"><h3 class="pmc_sec_title">Ethics approval and consent to participate</h3>
<p id="Par39">This study was approved by each research site’s institutional review board or independent ethics committee and performed in accordance with the principles of the World Medical Association Declaration of Helsinki. Informed consent was obtained from participants prior to study enrollment.</p></section><section id="FPar2"><h3 class="pmc_sec_title">Consent for publication</h3>
<p id="Par40">Not applicable.</p></section><section id="FPar56"><h3 class="pmc_sec_title">Prior related presentations</h3>
<p id="Par41">Data from this manuscript have been presented, in part, at the American Society of Clinical Oncology Annual Meeting; Chicago, IL, USA; May 31-June 4, 2024.</p></section><section id="FPar3"><h3 class="pmc_sec_title">Competing interests</h3>
<p id="Par42">EH: reports research funding (all payments to institution): AbbVie, Acerta Pharma, Accutar Biotechnology, ADC Therapeutics, AKESOBIO Australia, Amgen, Aravive, ArQule, Artios, Arvinas, AstraZeneca, AtlasMedx, BeiGene, Black Diamond, Bliss BioPharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Cascadian Therapeutics, Clovis, Compugen, Context Therapeutics, Cullinan, Curis, CytomX, Daiichi Sankyo, Dana Farber Cancer Institute, Dantari, Deciphera, Duality Biologics, eFFECTOR Therapeutics, Eisai, Ellipses Pharma, Elucida Oncology, EMD Serono, Fochon Pharmaceuticals, FujiFilm, G1 Therapeutics, Gilead Sciences, H3 Biomedicine, Harpoon, Hutchinson MediPharma, Immunogen, Immunomedics, Incyte, Infinity Pharmaceuticals, Inspirna, InventisBio, Jacobio, Karyopharm, K-Group Beta, Kind Pharmaceuticals, Leap Therapeutics, Lilly, Loxo Oncology, Lycera, Mabspace Biosciences, Macrogenics, MedImmune, Mersana, Merus, Millennium, Molecular Templates, Myriad Genetic Laboratories, Novartis, Nucana, Olema, OncoMed, Oncothyreon, ORIC Pharmaceuticals, Orinove, Orum Therapeutics, Pfizer, PharmaMar, Pieris Pharmaceuticals, Pionyr Immunotherapeutics, Plexxikon, Prelude Therapeutics, Profound Bio, Radius Health, Regeneron, Relay Therapeutics, Repertoire Immune Medicine, Rgenix, Roche/Genentech, SeaGen, Sermonix Pharmaceuticals, Shattuck Labs, Silverback Therapeutics, StemCentRx, Stemline Therapeutics, Sutro, Syndax, Syros, Taiho, TapImmune, Tesaro, Tolmar, Torque Therapeutics, Treadwell Therapeutics, Verastem, Zenith Epigenetics, Zymeworks; consulting/advisory role (all payments to institution): Accutar Biotechnology, Arvinas, AstraZeneca, Circle Pharma, Daiichi Sankyo, Entos, Gilead Sciences, IQVIA, Janssen, Jazz Pharmaceuticals, Jefferies LLC, Johnson and Johnson, Lilly, Medical Pharma Services, Mersana Therapeutics, Olema Pharmaceuticals, Pfizer, Roche/Genentech, Shorla Pharma, Stemline Therapeutics, Tempus Labs, Theratechnologies, Tubulis, Zentalis Pharmaceuticals. TP: reports consulting or advisory roles with AstraZeneca, AstraZeneca, Carrick Therapeutics, Daiichi Sankyo/AstraZeneca, DualityBio, Gilead Sciences, Jazz Pharmaceuticals, Kestrel Therapeutics, Merck, Novartis, Pfizer, Scorpion Therapeutics, Seagen, Sermonix Pharmaceuticals, Stemline Therapeutics; speakers’ bureau roles with AstraZeneca, Gilead Sciences, SeaGen, Stemline Therapeutics; research funding from Arvinas, AstraZeneca/Daiichi Sankyo, Dantari, G1 Therapeutics, H3 Biomedicine, HiberCell, Novartis, Novartis, Olema Pharmaceuticals, Orinove, Pfizer, Sanofi, Scorpion Therapeutics, Seagen, Zymeworks. JSW: reports consulting or advisory roles with Fusion Pharmaceuticals, Kanaph Therapeutics; speakers’ bureaus roles with AstraZeneca, Eisai; research funding from Accutar Biotech, Adagene, Agenus, Allorion Therapeutics, Artios, Astellas Pharma, AstraZeneca, Bayer Health, BeiGene, Bicycle Therapeutics, BioNTech, Biostar, BioTheryX, Blueprint Medicines, BMS GmbH &amp; Co. KG, Boehringer Ingelheim, C4 Therapeutics, Celgene, Centessa Pharmaceuticals, Coherus Biosciences, Compugen, Cullinan Oncology, cyteir, Daiichi Sankyo, Ellipses Pharma, Erasca, Inc, Forty Seven, Genentech/Roche, Georgiamune, GlaxoSmithKline, H3 Biomedicine, Hotspot Therapeutics, IgM Biosciences, Immune-Onc Therapeutics, Immunitas, Immunogen, Janssen Research &amp; Development, Jazz Pharmaceuticals (Inst); Kineta (Inst); Klus Pharma (Inst); Kura Oncology, Kymab, Loxo, LSK BioPharma, MabSpace Biosciences, Macrogenics, Medikine, Merck, Mersana, Moderna Therapeutics, NGM Biopharmaceuticals, Nurix, Olema Oncology, Phoenix Pharmaceuticals, Prelude Therapeutics, PureTech, Pyxis, QiLu Pharmaceutical, Relay Therapeutics, Revolution Medicine, Ribon Therapeutics, Sanofi, Seven and Eight Biopharmaceuticals, Step Pharma, Syndax, Tango Therapeutics, TeneoBio, Treadwell Therapeutics, Vividion Therapeutics, Xencor, Zymeworks. AM: reports consulting or advisory roles with Eisai, Lilly, Seagen; research funding from Dantari Pharmaceuticals, Eisai, Eisai, F. Hoffmann LaRoche, Freenome, Genentech/Roche, Lilly, Merck Sharp &amp; Dohme Corp., Merrimack, Millenium Pharmaceuticals, Molecular Templates, Novartis, Pfizer, Seagen, Suzhou Zanrong Pharma, Tempus; other relationship with Taiho Pharmaceutical; uncompensated relationship with Puma Biotechnology. SJ: reports receiving honoraria from AstraZeneca, Lilly, Pfizer; consulting or advisory roles with Genzyme, Lilly, Pfizer, Puma Biotechnology; research funding from Pfizer; expert testimony with Novartis. ECD: reports consulting or advisory roles with Novartis, Sanofi; research funding from Boehringer Ingelheim, G1 Therapeutics, H3 Biomedicine, Meryx Pharmaceuticals, Pfizer. CV: reports employment from Flatiron Health (wife); honoraria from Cardinal Health, Daiichi Sankyo/AstraZeneca, Daiichi Sankyo/AstraZeneca, Gilead Sciences, Guidepoint Global, Novartis, Pfizer, Seagen; consulting or advisory roles with AstraZeneca, Daiichi Sankyo, Gilead Sciences; research funding from AstraZeneca, AstraZeneca/Daiichi Sankyo, Genentech, H3 Biomedicine, Incyte, Innocrin Pharma, Novartis, Pfizer, Pharmacyclics, Roche, Seagen, TRACON Pharma, Zymeworks; other relationship with Daiichi Sankyo, Puma Biotechnology, Takeda; uncompensated relationships with Genentech. AA: reports stock and other ownership interests with AstraZeneca; consulting and advisory roles with Gilead Sciences, MSD, Roche; research funding from AstraZeneca/MedImmune; travel, accommodations, and expenses from Gilead Science, MSD Oncology, Novartis, Roche; other relationships with Gilead Sciences. PM: reports leadership with Alessa Therapeutics; stock and other ownership interests with Alessa Therapeutics, AtlasMedx, Hap10; OnKure, Parthenon Therapeutics, RasCal; honoraria from JNJ, Olema Pharmaceuticals, Parthenon Therapeutics; consulting or advisory roles with Alessa Therapeutics, AtlasMedx, Olema Pharmaceuticals, RasCal; research funding from Actuate Therapeutics, Amgen, Arch Oncology, Arvinas, Arvinas, Bliss Biopharmaceutical, Blueprint Medicines, Bristol-Myers Squibb, Cyteir; Deciphera, Genentech/Roche, GlaxoSmithKline, H3 Biomedicine, IgM Biosciences, Immune Design, InventisBio, Merck, Novartis, ORIC Pharmaceuticals, Pfizer, PMV Pharma, Relay Therapeutics, Revolution Medicines, Sanofi, Seagen, Skorpion, Tempest Therapeutics, Xencor, Xynomic Pharma; a UCSF patent on using silastic implants to deliver anticancer agents. NU: reports honoraria from M3; consulting or advisory roles with bioTheranostics, Pfizer. GSW: reports receiving research funding from AbbVie, AstraZeneca, Daiichi Sankyo/AstraZeneca, Eisai/H3 Biomedicine, G1 Therapeutics, Genentech, Gilead Sciences, Hutchison MediPharma, Innocrin Pharma, Lilly, Macrogenics, NanoString Technologies, Novartis, Odonate Therapeutics, Oncothyreon, Pfizer, Roche, Seagen, Taiho Pharmaceutical. FK: has nothing to declare. TS: reports employment and stock ownership with Eisai. YR: reports employment from Eisai. KY: reports employment from Eisai. DJ: reports stock and other ownership interests with PIC Therapeutics, Relay Therapeutics, Vibliome Therapeutics; consulting or advisory roles with AstraZeneca, Eisai, Genentech, Lilly, MapKure, Novartis; Pfizer, PIC Therapeutics, Relay Therapeutics, Vibliome Therapeutics; research funding from Amgen, Arvinas, AstraZeneca, Blueprint Medicines, Eisai, Genentech, Infinity Pharmaceuticals, InventisBio, Novartis, Pfizer, Ribon Therapeutics, Scorpion Therapeutics, Syros Pharmaceuticals, Takeda.</p></section></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Footnotes</h2>
<div class="fn-group p font-secondary-light font-sm"><div class="fn p" id="fn1">
<p><strong>Publisher’s note</strong></p>
<p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</div></div></section><section id="Bib1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="Bib1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="CR1">
<span class="label">1.</span><cite>Lumachi F, Brunello A, Maruzzo M, Basso U, Basso SM. Treatment of estrogen receptor-positive breast cancer. Curr Med Chem. 2013;20:596–604.
</cite> [<a href="https://doi.org/10.2174/092986713804999303" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23278394/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lumachi%20F,%20Brunello%20A,%20Maruzzo%20M,%20Basso%20U,%20Basso%20SM.%20Treatment%20of%20estrogen%20receptor-positive%20breast%20cancer.%20Curr%20Med%20Chem.%202013;20:596%E2%80%93604." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR2">
<span class="label">2.</span><cite>Beslija S, Bonneterre J, Burstein HJ, Cocquyt V, Gnant M, Heinemann V, et al. Third consensus on medical treatment of metastatic breast cancer. Ann Oncol. 2009;20:1771–85.
</cite> [<a href="https://doi.org/10.1093/annonc/mdp261" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19608616/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Beslija%20S,%20Bonneterre%20J,%20Burstein%20HJ,%20Cocquyt%20V,%20Gnant%20M,%20Heinemann%20V,%20et%20al.%20Third%20consensus%20on%20medical%20treatment%20of%20metastatic%20breast%20cancer.%20Ann%20Oncol.%202009;20:1771%E2%80%9385." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR3">
<span class="label">3.</span><cite>Bidard FC, Kaklamani VG, Neven P, Streich G, Montero AJ, Forget F, et al. Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase III EMERALD trial. J Clin Oncol. 2022;40:3246–56.</cite> [<a href="https://doi.org/10.1200/JCO.22.00338" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9553388/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35584336/" class="usa-link">PubMed</a>]</li>
<li id="CR4">
<span class="label">4.</span><cite>Lee EY, Lee DW, Lee KH, Im SA. Recent developments in the therapeutic landscape of advanced or metastatic hormone receptor-positive breast cancer. Cancer Res Treat. 2023;55:1065–76.
</cite> [<a href="https://doi.org/10.4143/crt.2023.846" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10582540/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37817306/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lee%20EY,%20Lee%20DW,%20Lee%20KH,%20Im%20SA.%20Recent%20developments%20in%20the%20therapeutic%20landscape%20of%20advanced%20or%20metastatic%20hormone%20receptor-positive%20breast%20cancer.%20Cancer%20Res%20Treat.%202023;55:1065%E2%80%9376." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR5">
<span class="label">5.</span><cite>Hartkopf AD, Grischke EM, Brucker SY. Endocrine-resistant breast cancer: mechanisms and treatment. Breast Care (Basel). 2020;15:347–54.
</cite> [<a href="https://doi.org/10.1159/000508675" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7490658/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32982644/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Hartkopf%20AD,%20Grischke%20EM,%20Brucker%20SY.%20Endocrine-resistant%20breast%20cancer:%20mechanisms%20and%20treatment.%20Breast%20Care%20(Basel).%202020;15:347%E2%80%9354." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR6">
<span class="label">6.</span><cite>Chandarlapaty S, Chen D, He W, Sung P, Samoila A, You D, et al. Prevalence of ESR1 mutations in cell-free DNA and outcomes in metastatic breast cancer: a secondary analysis of the BOLERO-2 clinical trial. JAMA Oncol. 2016;2:1310–5.
</cite> [<a href="https://doi.org/10.1001/jamaoncol.2016.1279" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5063698/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27532364/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chandarlapaty%20S,%20Chen%20D,%20He%20W,%20Sung%20P,%20Samoila%20A,%20You%20D,%20et%20al.%20Prevalence%20of%20ESR1%20mutations%20in%20cell-free%20DNA%20and%20outcomes%20in%20metastatic%20breast%20cancer:%20a%20secondary%20analysis%20of%20the%20BOLERO-2%20clinical%20trial.%20JAMA%20Oncol.%202016;2:1310%E2%80%935." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR7">
<span class="label">7.</span><cite>Lindeman GJ, Fernando TM, Bowen R, Jerzak KJ, Song X, Decker T, et al. VERONICA: randomized phase II study of fulvestrant and venetoclax in ER-positive metastatic breast cancer post-CDK4/6 inhibitors - efficacy, safety, and biomarker results. Clin Cancer Res. 2022;28:3256–67.
</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-21-3811" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9662928/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35583555/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lindeman%20GJ,%20Fernando%20TM,%20Bowen%20R,%20Jerzak%20KJ,%20Song%20X,%20Decker%20T,%20et%20al.%20VERONICA:%20randomized%20phase%20II%20study%20of%20fulvestrant%20and%20venetoclax%20in%20ER-positive%20metastatic%20breast%20cancer%20post-CDK4/6%20inhibitors%20-%20efficacy,%20safety,%20and%20biomarker%20results.%20Clin%20Cancer%20Res.%202022;28:3256%E2%80%9367." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR8">
<span class="label">8.</span><cite>Toy W, Weir H, Razavi P, Lawson M, Goeppert AU, Mazzola AM, et al. Activating ESR1 mutations differentially affect the efficacy of ER antagonists. Cancer Discov. 2017;7:277–87.
</cite> [<a href="https://doi.org/10.1158/2159-8290.CD-15-1523" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5340622/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27986707/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Toy%20W,%20Weir%20H,%20Razavi%20P,%20Lawson%20M,%20Goeppert%20AU,%20Mazzola%20AM,%20et%20al.%20Activating%20ESR1%20mutations%20differentially%20affect%20the%20efficacy%20of%20ER%20antagonists.%20Cancer%20Discov.%202017;7:277%E2%80%9387." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR9">
<span class="label">9.</span><cite>Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375:1925–36.
</cite> [<a href="https://doi.org/10.1056/NEJMoa1607303" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27959613/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Finn%20RS,%20Martin%20M,%20Rugo%20HS,%20Jones%20S,%20Im%20SA,%20Gelmon%20K,%20et%20al.%20Palbociclib%20and%20letrozole%20in%20advanced%20breast%20cancer.%20N%20Engl%20J%20Med.%202016;375:1925%E2%80%9336." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR10">
<span class="label">10.</span><cite>Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol. 2018;29:1541–7.
</cite> [<a href="https://doi.org/10.1093/annonc/mdy155" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29718092/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Hortobagyi%20GN,%20Stemmer%20SM,%20Burris%20HA,%20Yap%20YS,%20Sonke%20GS,%20Paluch-Shimon%20S,%20et%20al.%20Updated%20results%20from%20MONALEESA-2,%20a%20phase%20III%20trial%20of%20first-line%20ribociclib%20plus%20letrozole%20versus%20placebo%20plus%20letrozole%20in%20hormone%20receptor-positive,%20HER2-negative%20advanced%20breast%20cancer.%20Ann%20Oncol.%202018;29:1541%E2%80%937." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR11">
<span class="label">11.</span><cite>Turner NC, Slamon DJ, Ro J, Bondarenko I, Im SA, Masuda N, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med. 2018;379:1926–36.</cite> [<a href="https://doi.org/10.1056/NEJMoa1810527" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30345905/" class="usa-link">PubMed</a>]</li>
<li id="CR12">
<span class="label">12.</span><cite>Jhaveri KL, Neven P, Casalnuovo ML, Kim SB, Tokunaga E, Aftimos P, et al. Imlunestrant with or without abemaciclib in advanced breast cancer. N Engl J Med. 2025;392:1189–202.
</cite> [<a href="https://doi.org/10.1056/NEJMoa2410858" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39660834/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Jhaveri%20KL,%20Neven%20P,%20Casalnuovo%20ML,%20Kim%20SB,%20Tokunaga%20E,%20Aftimos%20P,%20et%20al.%20Imlunestrant%20with%20or%20without%20abemaciclib%20in%20advanced%20breast%20cancer.%20N%20Engl%20J%20Med.%202025;392:1189%E2%80%93202." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR13">
<span class="label">13.</span><cite>Zhou FH, Downton T, Freelander A, Hurwitz J, Caldon CE, Lim E. CDK4/6 inhibitor resistance in estrogen receptor positive breast cancer, a 2023 perspective. Front Cell Dev Biol. 2023;11:1148792.</cite> [<a href="https://doi.org/10.3389/fcell.2023.1148792" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10073728/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37035239/" class="usa-link">PubMed</a>]</li>
<li id="CR14">
<span class="label">14.</span><cite>Furman C, Puyang X, Zhang Z, Wu ZJ, Banka D, Aithal KB, et al. Covalent ERα antagonist H3B-6545 demonstrates encouraging preclinical activity in therapy-resistant breast cancer. Mol Cancer Ther. 2022;21:890–902.
</cite> [<a href="https://doi.org/10.1158/1535-7163.MCT-21-0378" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9381127/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35642432/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Furman%20C,%20Puyang%20X,%20Zhang%20Z,%20Wu%20ZJ,%20Banka%20D,%20Aithal%20KB,%20et%20al.%20Covalent%20ER%CE%B1%20antagonist%20H3B-6545%20demonstrates%20encouraging%20preclinical%20activity%20in%20therapy-resistant%20breast%20cancer.%20Mol%20Cancer%20Ther.%202022;21:890%E2%80%93902." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR15">
<span class="label">15.</span><cite>Puyang X, Furman C, Zheng GZ, Wu ZJ, Banka D, Aithal K, et al. Discovery of selective estrogen receptor covalent antagonists for the treatment of ERα<sup>WT</sup> and ERα<sup>MUT</sup> breast cancer. Cancer Discov. 2018;8:1176–93.</cite> [<a href="https://doi.org/10.1158/2159-8290.CD-17-1229" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29991605/" class="usa-link">PubMed</a>]</li>
<li id="CR16">
<span class="label">16.</span><cite>Hamilton EP, Wang JS, Pluard TJ, Johnston SRD, Morikawa A, Dees EC et al. Phase I/II study of H3B-6545, a novel selective estrogen receptor covalent antagonist (SERCA), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer [abstract]. J Clin Oncol. 2021;39(15 Suppl):Abstract 1018.</cite>
</li>
<li id="CR17">
<span class="label">17.</span><cite>Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/college of American pathologists clinical practice guideline update. Arch Pathol Lab Med. 2014;138:241–56.
</cite> [<a href="https://doi.org/10.5858/arpa.2013-0953-SA" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4086638/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24099077/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wolff%20AC,%20Hammond%20ME,%20Hicks%20DG,%20Dowsett%20M,%20McShane%20LM,%20Allison%20KH,%20et%20al.%20Recommendations%20for%20human%20epidermal%20growth%20factor%20receptor%202%20testing%20in%20breast%20cancer:%20American%20society%20of%20clinical%20oncology/college%20of%20American%20pathologists%20clinical%20practice%20guideline%20update.%20Arch%20Pathol%20Lab%20Med.%202014;138:241%E2%80%9356." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR18">
<span class="label">18.</span><cite>Patel R, Klein P, Tiersten A, Sparano JA. An emerging generation of endocrine therapies in breast cancer: a clinical perspective. NPJ Breast Cancer. 2023;9:20.
</cite> [<a href="https://doi.org/10.1038/s41523-023-00523-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10076370/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37019913/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Patel%20R,%20Klein%20P,%20Tiersten%20A,%20Sparano%20JA.%20An%20emerging%20generation%20of%20endocrine%20therapies%20in%20breast%20cancer:%20a%20clinical%20perspective.%20NPJ%20Breast%20Cancer.%202023;9:20." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR19">
<span class="label">19.</span><cite>Johnston SRD, Pluard TJ, Wang JS, Hamilton EP, Song T, Rong Y et al. H3B-6545 + palbociclib in patients (pts) with locally advanced/metastatic estrogen receptor-positive (ER+), HER2 negative (–) breast cancer (BC) [abstract]. J Clin Oncol. 2024;42(16 Suppl):Abstract 1051.</cite>
</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adsm93_" lang="en" class="supplementary-materials"><h3 class="pmc_sec_title">Supplementary Materials</h3>
<section class="sm xbox font-sm" id="db_ds_supplementary-material1_reqid_"><div class="media p"><div class="caption">
<a href="/articles/instance/12363031/bin/13058_2025_2069_MOESM1_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">Supplementary Material 1</a><sup> (871.6KB, docx) </sup>
</div></div></section></section><section id="_adda93_" lang="en" class="data-availability-statement"><h3 class="pmc_sec_title">Data Availability Statement</h3>
<p>The data will not be available for sharing at this time because the data are commercially confidential. However, Eisai Inc. will consider written requests to share the data on a case-by-case basis.</p></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Breast Cancer Research : BCR are provided here courtesy of <strong>BMC</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1186/s13058-025-02069-8"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/13058_2025_Article_2069.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (2.0 MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12363031/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12363031/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12363031%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12363031/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12363031/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12363031/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40830892/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12363031/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40830892/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12363031/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12363031/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="i5jRkMLnzLiM3DMgYsqmjcjftf5IF93IYEGiVGuHkpypMyxGEnpd4zjeRQPz7aNm">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
    

    </body>
</html>
